1
|
Walter LA, Prados M, Lloyd A, Sontheimer S, Heimann M, Rodgers JB, Hand DT, Franco R. Birth cohort-specific consideration in an Emergency Department Hepatitis C Testing Programme: A description of age-related characteristics and outcomes. J Viral Hepat 2024; 31:233-239. [PMID: 38366787 DOI: 10.1111/jvh.13930] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/08/2023] [Revised: 01/15/2024] [Accepted: 02/10/2024] [Indexed: 02/18/2024]
Abstract
The emergency department (ED) has increasingly become an important public health partner in non-targeted hepatitis C virus (HCV) testing and referral to care efforts. HCV has traditionally been an infection associated with the Baby Boomer generation; however, recent exacerbation of the opioid epidemic has resulted in a growing number of younger cohorts, namely Millennials, also impacted by HCV. Examination of this age-related demographic shift, including subsequent linkage success and linkage barriers, from the perspective of an ED-based testing and linkage programme may have implications for future population and health systems interventions. A retrospective descriptive chart review was performed, inclusive of data from August 2015 through December 2020. We compared the quantity of positive HCV screening antibody (Ab) and confirmatory (RNA) tests and further considered linkage rates and correlative demographics (e.g. gender, race). Patient barriers to HCV care linkage (e.g. substance misuse, lack of health insurance, homelessness) were also evaluated. The data set was disaggregated by birth cohort to include Silent Generation (SG) (1928-45), Baby Boomer (BB) (1946-64), Generation X (Gen X) (1965-80), Millennial (1981-96) and Generation Z (1997-2012). Descriptive statistics and chi-square analysis were performed. Overall, 83,817 patients were tested for HCV (50.6% of eligible); 6187 (7.4%) were HCV Ab positive, and 2665 were HCV RNA positive (3.2%). RNA-positive individuals were more likely to be white (70.4%) and male (67.7%); generational distribution was similar (BB 33.3%, Gen X 32.0% and Millennials 32.7%). Amongst Ab-positive patients, white (45.5%), male (47.2%) and Millennial (49.7%) individuals were most likely to be RNA-positive. Overall, 28.1% of the RNA-positive cohort successfully linked to care; linkage to care rates were significantly higher in older generations (38.1% in BB vs. 17.8% in Millennials) (p < .00001). Over 90% were identified as having at least one linkage to care barrier. Younger generations (Gen X and Millennials) were disproportionately impacted by linkage barriers, including incarceration, lack of health insurance, history of mental health and substance use disorders, as well as history of or active injection drug use (IDU) (p < .00001). Older generations (SG and BB) were more likely to be impacted by competing medical comorbidities (p < .00001). The ED population represents a particularly vulnerable, at-risk cohort with a high prevalence of HCV and linkage to care barriers. While past HCV-specific recommendations and interventions have focused on Baby Boomers, this data suggests that younger generations, including Gen X and Millennials, are increasingly affected by HCV and face disparate social risk and social need factors which impede definitive care linkage and treatment.
Collapse
Affiliation(s)
- Lauren A Walter
- Department of Emergency Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA
| | - Myles Prados
- Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA
| | - Audrey Lloyd
- Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA
| | - Sylvie Sontheimer
- Department of Emergency Medicine, Boston Medical Center, Boston, Massachusetts, USA
| | - Matthew Heimann
- Department of Emergency Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA
| | - Joel B Rodgers
- Division of Acute Care Surgery, Department of Surgery, University of Alabama at Birmingham, Birmingham, Alabama, USA
| | - Delissa T Hand
- O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama, USA
| | - Ricardo Franco
- Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA
| |
Collapse
|
2
|
Enea M, Nuekaew A, Franco R, Pereira E. Gold Nanoprobes for Detection of a Crucial EGFR Deletion for Early Diagnosis of Non-Small-Cell Lung Cancer. Biosensors (Basel) 2024; 14:162. [PMID: 38667155 PMCID: PMC11048279 DOI: 10.3390/bios14040162] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/05/2024] [Revised: 03/25/2024] [Accepted: 03/27/2024] [Indexed: 04/28/2024]
Abstract
Gold nanoparticles (AuNPs) exhibit improved optical and spectral properties compared to bulk materials, making them suitable for the detection of DNA, RNA, antigens, and antibodies. Here, we describe a simple, selective, and rapid non-cross linking detection assay, using approx. 35 nm spherical Au nanoprobes, for a common mutation occurring in exon 19 of the epidermal growth factor receptor (EGFR), associated with non-small-cell lung cancer cells. AuNPs were synthesized based on the seed-mediated growth method and functionalized with a specific 16 bp thiolated oligonucleotide using a pH-assisted method. Both AuNPs and Au nanoprobes proved to be highly stable and monodisperse through ultraviolet-visible spectrophotometry, dynamic light scattering (DLS), and electrophoretic light scattering (ELS). Our results indicate a detection limit of 1.5 µg mL-1 using a 0.15 nmol dm-3 Au nanoprobe concentration. In conclusion, this work presents an effective possibility for a straightforward, fast, and inexpensive alternative for the detection of DNA sequences related to lung cancer, leading to a potential platform for early diagnosis of lung cancer patients.
Collapse
Affiliation(s)
- Maria Enea
- LAQV/REQUIMTE, Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade do Porto, Rua Campo Alegre, 687, 4169-007 Porto, Portugal; (A.N.); (E.P.)
| | - Anupong Nuekaew
- LAQV/REQUIMTE, Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade do Porto, Rua Campo Alegre, 687, 4169-007 Porto, Portugal; (A.N.); (E.P.)
| | - Ricardo Franco
- Associate Laboratory i4HB, Institute for Health and Bioeconomy, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, 2819-516 Caparica, Portugal
- UCIBIO, Applied Molecular Biosciences Unit, Departamento de Química, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, 2819-516 Caparica, Portugal
| | - Eulália Pereira
- LAQV/REQUIMTE, Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade do Porto, Rua Campo Alegre, 687, 4169-007 Porto, Portugal; (A.N.); (E.P.)
| |
Collapse
|
3
|
Talal AH, Dharia A, Kapadia SN, Tyson GL, Birch S, Zerzan-Thul J, Sullivan D, Britton E, Wethington E, Gonzalez CJ, Fliss M, Mizroch B, McCall F, Lloyd AR, Shapiro MF, Franco R. Hepatitis C Virus Elimination Programs in Louisiana and Washington: Importance of Screening and Surveillance Systems. J Public Health Manag Pract 2024; 30:208-212. [PMID: 37594263 PMCID: PMC10833194 DOI: 10.1097/phh.0000000000001808] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/19/2023]
Abstract
The US government has established a national goal of hepatitis C virus (HCV) elimination by 2030. To date, most HCV elimination planning and activity have been at the state level. Fifteen states presently have publicly available HCV elimination plans. In 2019, Louisiana and Washington were the first states to initiate 5-year funded HCV elimination programs. These states differ on motivation for pursuing HCV elimination and ranking on several indicators. Simultaneously, however, they have emphasized several similar elimination components including HCV screening promotion through public awareness, screening expansion, surveillance enhancement (including electronic reporting and task force development), and harm reduction. The 13 other states with published elimination plans have proposed the majority of the elements identified by Louisiana and Washington, but several have notable gaps. Louisiana's and Washington's comprehensive plans, funding approaches, and programs provide a useful framework that can move states and the nation toward HCV elimination.
Collapse
Affiliation(s)
- Andrew H. Talal
- Division of Gastroenterology, Hepatology and Nutrition, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York (Drs Talal and Dharia); Divisions of Infectious Diseases (Dr Kapadia) and General Internal Medicine (Drs Gonzalez and Shapiro), Weill Cornell Medicine, New York, New York; Louisiana Department of Health, New Orleans, Louisiana (Drs Tyson, Mizroch, and McCall and Ms Britton); Washington State Healthcare Authority, Olympia, Washington (Drs Sullivan and Zerzan-Thul and Mss Birch and Fliss); Cornell University, Ithaca, New York (Dr Wethington); and Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama (Drs Lloyd and Franco)
| | - Arpan Dharia
- Division of Gastroenterology, Hepatology and Nutrition, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York (Drs Talal and Dharia); Divisions of Infectious Diseases (Dr Kapadia) and General Internal Medicine (Drs Gonzalez and Shapiro), Weill Cornell Medicine, New York, New York; Louisiana Department of Health, New Orleans, Louisiana (Drs Tyson, Mizroch, and McCall and Ms Britton); Washington State Healthcare Authority, Olympia, Washington (Drs Sullivan and Zerzan-Thul and Mss Birch and Fliss); Cornell University, Ithaca, New York (Dr Wethington); and Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama (Drs Lloyd and Franco)
| | - Shashi N. Kapadia
- Division of Gastroenterology, Hepatology and Nutrition, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York (Drs Talal and Dharia); Divisions of Infectious Diseases (Dr Kapadia) and General Internal Medicine (Drs Gonzalez and Shapiro), Weill Cornell Medicine, New York, New York; Louisiana Department of Health, New Orleans, Louisiana (Drs Tyson, Mizroch, and McCall and Ms Britton); Washington State Healthcare Authority, Olympia, Washington (Drs Sullivan and Zerzan-Thul and Mss Birch and Fliss); Cornell University, Ithaca, New York (Dr Wethington); and Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama (Drs Lloyd and Franco)
| | - Gia L. Tyson
- Division of Gastroenterology, Hepatology and Nutrition, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York (Drs Talal and Dharia); Divisions of Infectious Diseases (Dr Kapadia) and General Internal Medicine (Drs Gonzalez and Shapiro), Weill Cornell Medicine, New York, New York; Louisiana Department of Health, New Orleans, Louisiana (Drs Tyson, Mizroch, and McCall and Ms Britton); Washington State Healthcare Authority, Olympia, Washington (Drs Sullivan and Zerzan-Thul and Mss Birch and Fliss); Cornell University, Ithaca, New York (Dr Wethington); and Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama (Drs Lloyd and Franco)
| | - Susan Birch
- Division of Gastroenterology, Hepatology and Nutrition, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York (Drs Talal and Dharia); Divisions of Infectious Diseases (Dr Kapadia) and General Internal Medicine (Drs Gonzalez and Shapiro), Weill Cornell Medicine, New York, New York; Louisiana Department of Health, New Orleans, Louisiana (Drs Tyson, Mizroch, and McCall and Ms Britton); Washington State Healthcare Authority, Olympia, Washington (Drs Sullivan and Zerzan-Thul and Mss Birch and Fliss); Cornell University, Ithaca, New York (Dr Wethington); and Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama (Drs Lloyd and Franco)
| | - Judy Zerzan-Thul
- Division of Gastroenterology, Hepatology and Nutrition, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York (Drs Talal and Dharia); Divisions of Infectious Diseases (Dr Kapadia) and General Internal Medicine (Drs Gonzalez and Shapiro), Weill Cornell Medicine, New York, New York; Louisiana Department of Health, New Orleans, Louisiana (Drs Tyson, Mizroch, and McCall and Ms Britton); Washington State Healthcare Authority, Olympia, Washington (Drs Sullivan and Zerzan-Thul and Mss Birch and Fliss); Cornell University, Ithaca, New York (Dr Wethington); and Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama (Drs Lloyd and Franco)
| | - Donna Sullivan
- Division of Gastroenterology, Hepatology and Nutrition, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York (Drs Talal and Dharia); Divisions of Infectious Diseases (Dr Kapadia) and General Internal Medicine (Drs Gonzalez and Shapiro), Weill Cornell Medicine, New York, New York; Louisiana Department of Health, New Orleans, Louisiana (Drs Tyson, Mizroch, and McCall and Ms Britton); Washington State Healthcare Authority, Olympia, Washington (Drs Sullivan and Zerzan-Thul and Mss Birch and Fliss); Cornell University, Ithaca, New York (Dr Wethington); and Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama (Drs Lloyd and Franco)
| | - Elizabeth Britton
- Division of Gastroenterology, Hepatology and Nutrition, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York (Drs Talal and Dharia); Divisions of Infectious Diseases (Dr Kapadia) and General Internal Medicine (Drs Gonzalez and Shapiro), Weill Cornell Medicine, New York, New York; Louisiana Department of Health, New Orleans, Louisiana (Drs Tyson, Mizroch, and McCall and Ms Britton); Washington State Healthcare Authority, Olympia, Washington (Drs Sullivan and Zerzan-Thul and Mss Birch and Fliss); Cornell University, Ithaca, New York (Dr Wethington); and Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama (Drs Lloyd and Franco)
| | - Elaine Wethington
- Division of Gastroenterology, Hepatology and Nutrition, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York (Drs Talal and Dharia); Divisions of Infectious Diseases (Dr Kapadia) and General Internal Medicine (Drs Gonzalez and Shapiro), Weill Cornell Medicine, New York, New York; Louisiana Department of Health, New Orleans, Louisiana (Drs Tyson, Mizroch, and McCall and Ms Britton); Washington State Healthcare Authority, Olympia, Washington (Drs Sullivan and Zerzan-Thul and Mss Birch and Fliss); Cornell University, Ithaca, New York (Dr Wethington); and Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama (Drs Lloyd and Franco)
| | - Christopher J. Gonzalez
- Division of Gastroenterology, Hepatology and Nutrition, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York (Drs Talal and Dharia); Divisions of Infectious Diseases (Dr Kapadia) and General Internal Medicine (Drs Gonzalez and Shapiro), Weill Cornell Medicine, New York, New York; Louisiana Department of Health, New Orleans, Louisiana (Drs Tyson, Mizroch, and McCall and Ms Britton); Washington State Healthcare Authority, Olympia, Washington (Drs Sullivan and Zerzan-Thul and Mss Birch and Fliss); Cornell University, Ithaca, New York (Dr Wethington); and Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama (Drs Lloyd and Franco)
| | - Mary Fliss
- Division of Gastroenterology, Hepatology and Nutrition, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York (Drs Talal and Dharia); Divisions of Infectious Diseases (Dr Kapadia) and General Internal Medicine (Drs Gonzalez and Shapiro), Weill Cornell Medicine, New York, New York; Louisiana Department of Health, New Orleans, Louisiana (Drs Tyson, Mizroch, and McCall and Ms Britton); Washington State Healthcare Authority, Olympia, Washington (Drs Sullivan and Zerzan-Thul and Mss Birch and Fliss); Cornell University, Ithaca, New York (Dr Wethington); and Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama (Drs Lloyd and Franco)
| | - Brandon Mizroch
- Division of Gastroenterology, Hepatology and Nutrition, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York (Drs Talal and Dharia); Divisions of Infectious Diseases (Dr Kapadia) and General Internal Medicine (Drs Gonzalez and Shapiro), Weill Cornell Medicine, New York, New York; Louisiana Department of Health, New Orleans, Louisiana (Drs Tyson, Mizroch, and McCall and Ms Britton); Washington State Healthcare Authority, Olympia, Washington (Drs Sullivan and Zerzan-Thul and Mss Birch and Fliss); Cornell University, Ithaca, New York (Dr Wethington); and Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama (Drs Lloyd and Franco)
| | - Frederic McCall
- Division of Gastroenterology, Hepatology and Nutrition, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York (Drs Talal and Dharia); Divisions of Infectious Diseases (Dr Kapadia) and General Internal Medicine (Drs Gonzalez and Shapiro), Weill Cornell Medicine, New York, New York; Louisiana Department of Health, New Orleans, Louisiana (Drs Tyson, Mizroch, and McCall and Ms Britton); Washington State Healthcare Authority, Olympia, Washington (Drs Sullivan and Zerzan-Thul and Mss Birch and Fliss); Cornell University, Ithaca, New York (Dr Wethington); and Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama (Drs Lloyd and Franco)
| | - Audrey R. Lloyd
- Division of Gastroenterology, Hepatology and Nutrition, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York (Drs Talal and Dharia); Divisions of Infectious Diseases (Dr Kapadia) and General Internal Medicine (Drs Gonzalez and Shapiro), Weill Cornell Medicine, New York, New York; Louisiana Department of Health, New Orleans, Louisiana (Drs Tyson, Mizroch, and McCall and Ms Britton); Washington State Healthcare Authority, Olympia, Washington (Drs Sullivan and Zerzan-Thul and Mss Birch and Fliss); Cornell University, Ithaca, New York (Dr Wethington); and Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama (Drs Lloyd and Franco)
| | - Martin F. Shapiro
- Division of Gastroenterology, Hepatology and Nutrition, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York (Drs Talal and Dharia); Divisions of Infectious Diseases (Dr Kapadia) and General Internal Medicine (Drs Gonzalez and Shapiro), Weill Cornell Medicine, New York, New York; Louisiana Department of Health, New Orleans, Louisiana (Drs Tyson, Mizroch, and McCall and Ms Britton); Washington State Healthcare Authority, Olympia, Washington (Drs Sullivan and Zerzan-Thul and Mss Birch and Fliss); Cornell University, Ithaca, New York (Dr Wethington); and Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama (Drs Lloyd and Franco)
| | - Ricardo Franco
- Division of Gastroenterology, Hepatology and Nutrition, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York (Drs Talal and Dharia); Divisions of Infectious Diseases (Dr Kapadia) and General Internal Medicine (Drs Gonzalez and Shapiro), Weill Cornell Medicine, New York, New York; Louisiana Department of Health, New Orleans, Louisiana (Drs Tyson, Mizroch, and McCall and Ms Britton); Washington State Healthcare Authority, Olympia, Washington (Drs Sullivan and Zerzan-Thul and Mss Birch and Fliss); Cornell University, Ithaca, New York (Dr Wethington); and Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama (Drs Lloyd and Franco)
| |
Collapse
|
4
|
Crosby JC, Lee RA, McGwin G, Heath SL, Burkholder GA, Gravett RM, Overton ET, Locks G, Fleece ME, Franco R, Nafziger S. A COVID-19 monitoring process for healthcare workers utilizing occupational health. Occup Med (Lond) 2024; 74:71-77. [PMID: 37995321 PMCID: PMC10875928 DOI: 10.1093/occmed/kqad114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2023] Open
Abstract
BACKGROUND Hospital-based occupational health (HBOH) is uniquely positioned to not only prevent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) transmission, but to care for healthcare workers (HCWs) sick with coronavirus disease 2019 (COVID-19). AIMS The primary objective of this study is to describe a system where HBOH services were adapted to provide a monitoring programme whereby HCWs with SARS-CoV-2 received daily evaluations and treatment options in order to improve access to care, and to report the clinical outcomes and predictors of hospitalization in HCWs enrolled in the programme. A secondary objective is to compare clinical outcomes to data on national HCWs with COVID-19. METHODS This retrospective cohort study used survey data collected on HCWs at a university health system with COVID-19 from 1 March 2020 through 1 December 2021. A firth regression model was used to examine the unadjusted and adjusted association between clinical factors and hospitalization. RESULTS The study cohort included 4814 HCWs with COVID-19. Overall hospitalizations were 119 (2%), and there were six deaths (0.12%). Predictors of hospitalization include several co-morbidities and symptoms. A total of 1835 HCWs monitored before vaccine or monoclonal antibody availability were compared with data on U.S. HCWs in a similar time period. The monitored HCWs had a lower rate of co-morbidities (19% versus 44%, P < 0.001), a lower hospitalization rate (3% versus 8% P < 0.001) and case-fatality rate (0.11% versus 0.95% P < 0.001). CONCLUSIONS This monitoring strategy for COVID-19 may be feasible for HBOH systems to implement and improve access to care, but more data are needed to determine if it improves outcomes.
Collapse
Affiliation(s)
- J C Crosby
- Department of Emergency Medicine, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, 35233, USA
| | - R A Lee
- Department of Medicine, Division of Infectious Diseases, Heerskin School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, 35233, USA
| | - G McGwin
- Department of Epidemiology, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama, 35233, USA
| | - S L Heath
- Department of Emergency Medicine, Heersink School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, 35233, USA
| | - G A Burkholder
- Department of Medicine, Division of Infectious Diseases, Heerskin School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, 35233, USA
| | - R M Gravett
- Department of Medicine, Division of Infectious Diseases, Heerskin School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, 35233, USA
| | - E T Overton
- Department of Medicine, Division of Infectious Diseases, Heerskin School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, 35233, USA
| | - G Locks
- UAB Employee Health, University of Alabama at Birmingham, Birmingham, Alabama, 35233, USA
| | - M E Fleece
- Department of Medicine, Division of Infectious Diseases, Heerskin School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, 35233, USA
| | - R Franco
- Department of Medicine, Division of Infectious Diseases, Heerskin School of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, 35233, USA
| | - S Nafziger
- Department of Health Policy and Organization, School of Public Health, University of Alabama at Birmingham, Birmingham, Alabama, 35233, USA
| |
Collapse
|
5
|
Walter LA, Wilson L, Farmer M, Roberson T, Hand DT, Franco R. Sustained virologic response from hepatitis C from an emergency department screening & linkage program: A retrospective review. Am J Emerg Med 2023; 72:178-182. [PMID: 37540919 DOI: 10.1016/j.ajem.2023.07.050] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/08/2023] [Revised: 06/18/2023] [Accepted: 07/26/2023] [Indexed: 08/06/2023] Open
Abstract
INTRODUCTION The role of the Emergency Department (ED) as a vital constituent in Hepatitis C (HCV) screening has become increasingly evident. A key component of the ED's role in HCV screening is the ability to effectively link HCV-RNA positive patients to definitive, HCV-specific care, to include direct-acting antiviral (DAA) medication with resultant sustained virologic response (SVR). We sought to consider the rate of HCV-specific linkage, DAA initiation, and SVR obtained in HCV patients identified from an ED screening program. METHODS A retrospective chart review was conducted in February of 2022 of all individuals who participated in an opt-out ED-based HCV screening program between January 2018 and December 2019. Data was disaggregated by race, gender, age/birth cohort, insurance status, and achievement of sustained virologic response (SVR). Bivariate analysis using Pearson's chi-square was utilized to compare outcomes based on insurance status, race, sex, and birth cohort. RESULTS Of 66,634 individuals screened for HCV during the study period, 885 (1.33%) patients were RNA-positive. Of those individuals, 121 (13.67%) were linked to HCV-specific care. Of those linked, the majority (66.9%) were male, white (66.1%; 33.1% Black), baby boomers or older (53.7%) and publicly insured (57.9%; private insurance 23.1%, self-pay 19%). Among linked patients, 88 (72.7%) started DAA medication. Mirroring linked demographics, majority were male (64.8%), white (64.8%), baby boomers or older (52.3%), and publicly insured (57.6%). White patients initiated on DAA were more likely to obtain SVR (64.9% versus 41.9% Black; p = .04) and uninsured patients were more likely to obtain SVR (82.4% versus 50.7% insured; p = .02). Bivariate consideration of SVR-patients specifically demonstrates that Black patients tended to be older, with significant overrepresentation of Baby boomers (77.5%) as compared to whites (37.5%; p < .0001). Black patients were also more likely to be publicly insured (82.5%) while white patients were more likely to have private insurance (28.8%) or be uninsured (26.3%) than their Black counterparts (12.5% and 5% respectively; p < .05). CONCLUSION An ED-based HCV screening program can result in successful HCV-specific linkage and care, to include DAA initiation and ultimately, SVR. Among linked patients, specific cohort considerations may demonstrate differences in age and insurance status which may have implications on DAA application and adherence, and therefore, individual ability to achieve SVR.
Collapse
Affiliation(s)
- Lauren A Walter
- Department of Emergency Medicine, University of Alabama at Birmingham, Birmingham, AL, United States of America.
| | - Logan Wilson
- Department of Emergency Medicine, University of Alabama at Birmingham, Birmingham, AL, United States of America
| | - Madeline Farmer
- University of Alabama at Birmingham, Heersink School of Medicine, United States of America
| | - Tinsley Roberson
- University of Alabama at Birmingham, Heersink School of Medicine, United States of America
| | - Delissa T Hand
- O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, AL, United States of America
| | - Ricardo Franco
- Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, United States of America
| |
Collapse
|
6
|
Minervini G, Franco R, Marrapodi MM, Fiorillo L, Cervino G, Cicciù M. The association between parent education level, oral health, and oral-related sleep disturbance. An observational crosssectional study. Eur J Paediatr Dent 2023; 24:218-223. [PMID: 37668455 DOI: 10.23804/ejpd.2023.1910] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 09/06/2023]
Abstract
AIM To explore the relationship between parents' education levels, children obesity, children oral health and oral-related sleep disorders. BACKGROUND Prevention of oral diseases in children is important for their long-term health. Parents play a crucial role in the health and wellness of their children. As such, it is important for parents to be well-informed about the importance of their children's oral health, as well as the steps they can take to ensure that their children receive the best possible care. METHODS Observational cross-sectional study. At the time of enrollment data regarding parents' employment status and parents' education level were collected. We also collected BMI and anamnestic data regarding the presence or not of oral-related sleep disorders in the last 3 months: snoring, chronic mouth breathing, sleep bruxism. Oral health was also evaluated for each subject through the DMFT (decayed, missing and filled teeth) index. CONCLUSION Parents' education levels influence several health outcomes, including oral health and the risk of obesity. In turn, obesity can represent a risk factor for oral-related sleep disturbances. Parents play a crucial role in the health and wellness of their children. As such, it is important for parents to be knowledgeable about the importance of their children's health, as well as the steps they can take to ensure that their children receive the best possible care.
Collapse
Affiliation(s)
- G Minervini
- Multidisciplinary Department of Medical, Surgical and Odontostomatological Specialties, University of Campania "Luigi Vanvitelli", Naples, Italy
| | - R Franco
- Department of Biomedicine and Prevention, University of University of Rome "Tor Vergata", Rome, Italy
| | - M M Marrapodi
- Department of Woman, Child and General and Specialist Surgery, University of Campania "Luigi Vanvitelli," Naples, Italy
| | - L Fiorillo
- School of Dentistry Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy
| | - G Cervino
- School of Dentistry Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy
| | - M Cicciù
- School of Dentistry Department of Biomedical and Dental Sciences and Morphofunctional Imaging, University of Messina, Messina, Italy
| |
Collapse
|
7
|
Bendaoudi L, Ouahrani T, Daouli A, Rerbal B, Boufatah RM, Morales-García Á, Franco R, Bedrane Z, Badawi M, Errandonea D. Electronic and electrocatalytic properties of PbTiO 3: unveiling the effect of strain and oxygen vacancy. Dalton Trans 2023; 52:11965-11980. [PMID: 37577968 DOI: 10.1039/d3dt01478a] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 08/15/2023]
Abstract
First-principles calculations based on density-functional theory have been used to investigate the effect of biaxial strain and oxygen vacancy on the electronic, photocatalytic, and electrocatalytic properties of PbTiO3 oxide. Our results show that PbTiO3 has a high exciton binding energy and a band gap that can be easily moderated with different strain regimes. From a reactivity viewpoint, the highly exothermic adsorption of hydrogen atoms in both pristine and strained PbTiO3 structures does not make it a potential electrocatalyst for the hydrogen evolution reaction. Fortunately, the presence of oxygen vacancies on the PbTiO3 surface induces moderate adsorption energies, making the reduced PbTiO3 suitable for hydrogen evolution reaction processes.
Collapse
Affiliation(s)
- L Bendaoudi
- Laboratory of Materials Discovery, Unit of Research Materials and Renewable Energies, LEPM-URMER, Université de Tlemcen 13000, Algeria
| | - T Ouahrani
- École supérieure en sciences appliquées, ESSA-Tlemcen, BB 165 RP Bel Horizon, Tlemcen 13000, Algeria.
- Laboratoire de Physique Théorique, Université de Tlemcen, BP 119, 13000, Algeria.
| | - A Daouli
- Université de Lorraine and CNRS, LPCT, UMR 7019, 54506 Vandoeuvre-lés-Nancy, France
| | - B Rerbal
- Laboratory of Materials Discovery, Unit of Research Materials and Renewable Energies, LEPM-URMER, Université de Tlemcen 13000, Algeria
| | - R M Boufatah
- Laboratoire de Physique Théorique, Université de Tlemcen, BP 119, 13000, Algeria.
| | - Á Morales-García
- Departament de Ciéncia de Materials i Química Física & Institut de Química Teórica i Computacional (IQTCUB), Universitat de Barcelona, c/Martí i Franquès 1-11, 08028 Barcelona, Spain
| | - R Franco
- (MALTA) Consolider Team and Departamento de Química Física y Analítica, Universidad de Oviedo, E-33006 Oviedo, Spain
| | - Z Bedrane
- Laboratoire de Physique Théorique, Université de Tlemcen, BP 119, 13000, Algeria.
| | - M Badawi
- Université de Lorraine and CNRS, LPCT, UMR 7019, 54506 Vandoeuvre-lés-Nancy, France
| | - D Errandonea
- Departamento de Física Aplicada - Instituto de Ciencia de Materiales, Matter at High Pressure (MALTA) Consolider Team, Universidad de Valencia, Edificio de Investigación, C/Dr. Moliner 50, Burjassot, 46100, Valencia, Spain.
| |
Collapse
|
8
|
Oliveira MJ, Caetano S, Dalot A, Sabino F, Calmeiro TR, Fortunato E, Martins R, Pereira E, Prudêncio M, Byrne HJ, Franco R, Águas H. A simple polystyrene microfluidic device for sensitive and accurate SERS-based detection of infection by malaria parasites. Analyst 2023; 148:4053-4063. [PMID: 37529888 PMCID: PMC10440799 DOI: 10.1039/d3an00971h] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2023] [Accepted: 07/27/2023] [Indexed: 08/03/2023]
Abstract
Early and accurate detection of infection by pathogenic microorganisms, such as Plasmodium, the causative agent of malaria, is critical for clinical diagnosis and ultimately determines the patient's outcome. We have combined a polystyrene-based microfluidic device with an immunoassay which utilises Surface-Enhanced Raman Spectroscopy (SERS) to detect malaria. The method can be easily translated to a point-of-care testing format and shows excellent sensitivity and specificity, when compared to the gold standard for laboratorial detection of Plasmodium infections. The device can be fabricated in less than 30 min by direct patterning on shrinkable polystyrene sheets of adaptable three-dimensional microfluidic chips. To validate the microfluidic system, samples of P. falciparum-infected red blood cell cultures were used. The SERS-based immunoassay enabled the detection of 0.0012 ± 0.0001% parasitaemia in a P. falciparum-infected red blood cell culture supernatant, an ∼7-fold higher sensitivity than that attained by most rapid diagnostic tests. Our approach successfully overcomes the main challenges of the current Plasmodium detection methods, including increased reproducibility, sensitivity, and specificity. Furthermore, our system can be easily adapted for detection of other pathogens and has excellent properties for early diagnosis of infectious diseases, a decisive step towards lowering their high burden on healthcare systems worldwide.
Collapse
Affiliation(s)
- Maria João Oliveira
- CENIMAT-i3N, Departamento de Ciência dos Materiais, Faculdade de Ciências e Tecnologia, FCT, Universidade Nova de Lisboa, and CEMOP/UNINOVA, 2829-516 Caparica, Portugal.
- Associate Laboratory i4HB - Institute for Health and Bioeconomy, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, 2829-516 Caparica, Portugal.
- UCIBIO - Applied Molecular Biosciences Unit, Departamento de Química, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, 2829-516 Caparica, Portugal
| | - Soraia Caetano
- Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028 Lisbon, Portugal
| | - Ana Dalot
- CENIMAT-i3N, Departamento de Ciência dos Materiais, Faculdade de Ciências e Tecnologia, FCT, Universidade Nova de Lisboa, and CEMOP/UNINOVA, 2829-516 Caparica, Portugal.
- Associate Laboratory i4HB - Institute for Health and Bioeconomy, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, 2829-516 Caparica, Portugal.
- UCIBIO - Applied Molecular Biosciences Unit, Departamento de Química, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, 2829-516 Caparica, Portugal
| | - Filipe Sabino
- CENIMAT-i3N, Departamento de Ciência dos Materiais, Faculdade de Ciências e Tecnologia, FCT, Universidade Nova de Lisboa, and CEMOP/UNINOVA, 2829-516 Caparica, Portugal.
- Associate Laboratory i4HB - Institute for Health and Bioeconomy, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, 2829-516 Caparica, Portugal.
- UCIBIO - Applied Molecular Biosciences Unit, Departamento de Química, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, 2829-516 Caparica, Portugal
| | - Tomás R Calmeiro
- CENIMAT-i3N, Departamento de Ciência dos Materiais, Faculdade de Ciências e Tecnologia, FCT, Universidade Nova de Lisboa, and CEMOP/UNINOVA, 2829-516 Caparica, Portugal.
| | - Elvira Fortunato
- CENIMAT-i3N, Departamento de Ciência dos Materiais, Faculdade de Ciências e Tecnologia, FCT, Universidade Nova de Lisboa, and CEMOP/UNINOVA, 2829-516 Caparica, Portugal.
| | - Rodrigo Martins
- CENIMAT-i3N, Departamento de Ciência dos Materiais, Faculdade de Ciências e Tecnologia, FCT, Universidade Nova de Lisboa, and CEMOP/UNINOVA, 2829-516 Caparica, Portugal.
| | - Eulália Pereira
- LAQV, REQUIMTE, Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade do Porto, Rua do Campo Alegre, s/n, 4169-007 Porto, Portugal
| | - Miguel Prudêncio
- Instituto de Medicina Molecular João Lobo Antunes, Faculdade de Medicina, Universidade de Lisboa, Av. Prof. Egas Moniz, 1649-028 Lisbon, Portugal
| | - Hugh J Byrne
- FOCAS Research Institute, Technological University Dublin, Camden Street, Dublin 8, Ireland
| | - Ricardo Franco
- Associate Laboratory i4HB - Institute for Health and Bioeconomy, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, 2829-516 Caparica, Portugal.
- UCIBIO - Applied Molecular Biosciences Unit, Departamento de Química, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, 2829-516 Caparica, Portugal
| | - Hugo Águas
- CENIMAT-i3N, Departamento de Ciência dos Materiais, Faculdade de Ciências e Tecnologia, FCT, Universidade Nova de Lisboa, and CEMOP/UNINOVA, 2829-516 Caparica, Portugal.
| |
Collapse
|
9
|
Kapadia SN, Zhang H, Gonzalez CJ, Sen B, Franco R, Hutchings K, Wethington E, Talal A, Lloyd A, Dharia A, Wells M, Bao Y, Shapiro MF. Hepatitis C Treatment Initiation Among US Medicaid Enrollees. JAMA Netw Open 2023; 6:e2327326. [PMID: 37540513 PMCID: PMC10403776 DOI: 10.1001/jamanetworkopen.2023.27326] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/23/2023] [Accepted: 06/16/2023] [Indexed: 08/05/2023] Open
Abstract
Importance Direct-acting antiviral (DAA) treatment for hepatitis C virus (HCV) infection is highly effective but remains underused. Understanding disparities in the delivery of DAAs is important for HCV elimination planning and designing interventions to promote equitable treatment. Objective To examine variations in the receipt of DAA in the 6 months following a new HCV diagnosis. Design, Setting, and Participants This retrospective cohort study used national Medicaid claims from 2017 to 2019 from 50 states, Washington DC, and Puerto Rico. Individuals aged 18 to 64 years with a new diagnosis of HCV in 2018 were included. A new diagnosis was defined as a claim for an HCV RNA test followed by an International Statistical Classification of Diseases and Related Health Problems, Tenth Revision (ICD-10) diagnosis code, after a 1-year lookback period. Main Outcomes and Measures Outcome was receipt of a DAA prescription within 6 months of diagnosis. Logistic regression was used to examine demographic factors and ICD-10-identified comorbidities associated with treatment initiation. Results Among 87 652 individuals, 43 078 (49%) were females, 12 355 (14%) were age 18 to 29 years, 35 181 (40%) age 30 to 49, 51 282 (46%) were non-Hispanic White, and 48 840 (49%) had an injection drug use diagnosis. Of these individuals, 17 927 (20%) received DAAs within 6 months of their first HCV diagnosis. In the regression analyses, male sex was associated with increased treatment initiation (OR, 1.24; 95% CI, 1.16-1.33). Being age 18 to 29 years (OR, 0.65; 95% CI, 0.50-0.85) and injection drug use (OR, 0.84; 95% CI, 0.75-0.94) were associated with decreased treatment initiation. After adjustment for state fixed effects, Asian race (OR, 0.50; 95% CI, 0.40-0.64), American Indian or Alaska Native race (OR, 0.68; 95% CI, 0.55-0.84), and Hispanic ethnicity (OR, 0.81; 95% CI, 0.71-0.93) were associated with decreased treatment initiation. Adjustment for state Medicaid policy did not attenuate the racial or ethnic disparities. Conclusions In this retrospective cohort study, HCV treatment initiation was low among Medicaid beneficiaries and varied by demographic characteristics and comorbidities. Interventions are needed to increase HCV treatment uptake among Medicaid beneficiaries and to address disparities in treatment among key populations, including younger individuals, females, individuals from minoritized racial and ethnic groups, and people who inject drugs.
Collapse
Affiliation(s)
- Shashi N. Kapadia
- Division of Infectious Diseases, Weill Cornell Medicine, New York, New York
- Department of Population Health Sciences, Weill Cornell Medicine, New York, New York
| | - Hao Zhang
- Department of Population Health Sciences, Weill Cornell Medicine, New York, New York
| | | | - Bisakha Sen
- Department of Health Policy and Organization, University of Alabama at Birmingham, Birmingham
| | - Ricardo Franco
- Division of Infectious Diseases, University of Alabama at Birmingham
| | - Kayla Hutchings
- Department of Population Health Sciences, Weill Cornell Medicine, New York, New York
| | - Elaine Wethington
- Department of Sociology and Department of Psychology, Cornell University, Ithaca, New York
| | - Andrew Talal
- Division of Gastroenterology, Hepatology, and Nutrition, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York
| | - Audrey Lloyd
- Division of Infectious Diseases, University of Alabama at Birmingham
| | - Arpan Dharia
- Division of Gastroenterology, Hepatology, and Nutrition, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, New York
| | - Martin Wells
- Department of Statistics and Data Science, Cornell University, Ithaca, New York
| | - Yuhua Bao
- Department of Population Health Sciences, Weill Cornell Medicine, New York, New York
| | - Martin F Shapiro
- Division of General Internal Medicine, Weill Cornell Medicine, New York, New York
| |
Collapse
|
10
|
Pinheiro A, Franco R, Makeeva I, Bueno J, Miamoto P, Franco A. 30 years of the ABFO study: Reproduction in a Brazilian sample. Morphologie 2023:S1286-0115(23)00029-2. [PMID: 37149420 DOI: 10.1016/j.morpho.2023.04.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/19/2023] [Revised: 04/19/2023] [Accepted: 04/19/2023] [Indexed: 05/08/2023]
Abstract
The ABFO study on third molar development is a benchmark in the scientific literature of dental age estimation. In its 30th anniversary, the study has been reproduced in the present external validation. Standardized comparative outcomes were obtained and discussed across studies. The sample consisted of 1.087 panoramic radiographs of Brazilian females (n=542, 49.87%) and males (n=545, 50.13%) between 14 and 22.9 years. All available third molars were classified into developmental stages following Mincer's adaptation of Demirjian's system (8 sequential stages, from A to H). The mean chronological age of individuals within each stage was assessed. The probability of an individual being ≥ 18 years was calculated for each third molar, sex and stage. Maxillary and mandibular third molars showed a similar development with an agreement between stages of about 90%. In general, males developed 0.5 years (6 months) earlier than females. The probability of being an adult increased considerably when at least one third molar is in stage G. Maxillary third molars had higher coefficients of determination (right: 0.704; left: 0.702), showing that statistical models with these teeth could explain better the age estimation outcomes. The reproducibility of the ABFO study on third molar development led to reference tables and probability measures for the studied Brazilian population.
Collapse
Affiliation(s)
- A Pinheiro
- Faculdade São Leopoldo Mandic, R. Jose-Rocha-Junqueira 13, 13.045-755 Campinas, SP, Brazil
| | - R Franco
- Department of Community and Preventive Dentistry, Federal University of Uberlândia, 38.400-902 Uberlândia, Minas Gerais, Brazil
| | - I Makeeva
- Department of Therapeutic Stomatology, Institute of Dentistry, Sechenov University, 119146 Moscow, Russia
| | - J Bueno
- Division of Oral Radiology, Faculdade São Leopoldo Mandic, Brazil
| | - P Miamoto
- Division of Forensic Odontology and Anthropology, Scientific Police of Santa Catarina, 88085-002 Florianopolis, Santa Catarina, Brazil
| | - A Franco
- Faculdade São Leopoldo Mandic, R. Jose-Rocha-Junqueira 13, 13.045-755 Campinas, SP, Brazil.
| |
Collapse
|
11
|
Martini G, Belli V, Napolitano S, Ciaramella V, Ciardiello D, Belli A, Izzo F, Avallone A, Selvaggi F, Menegon Tasselli F, Santaniello W, Franco R, Puig I, Ramirez L, Chicote I, Mancuso F, Caratu G, Serres X, Fasani R, Jimenez J, Ros J, Baraibar I, Mulet N, Della Corte CM, Troiani T, Vivancos A, Dienstmann R, Elez E, Palmer HG, Tabernero J, Martinelli E, Ciardiello F, Argilés G. Establishment of patient-derived tumor organoids to functionally inform treatment decisions in metastatic colorectal cancer. ESMO Open 2023; 8:101198. [PMID: 37119788 DOI: 10.1016/j.esmoop.2023.101198] [Citation(s) in RCA: 9] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2022] [Revised: 02/16/2023] [Accepted: 02/22/2023] [Indexed: 05/01/2023] Open
Abstract
BACKGROUND Metastatic colorectal cancer (mCRC) patients tend to have modest benefits from molecularly driven therapeutics. Patient-derived tumor organoids (PDTOs) represent an unmatched model to elucidate tumor resistance to therapy, due to their high capacity to resemble tumor characteristics. MATERIALS AND METHODS We used viable tumor tissue from two cohorts of patients with mCRC, naïve or refractory to treatment, respectively, for generating PDTOs. The derived models were subjected to a 6-day drug screening assay (DSA) with a comprehensive pipeline of chemotherapy and targeted drugs against almost all the actionable mCRC molecular drivers. For the second cohort DSA data were matched with those from PDTO genotyping. RESULTS A total of 40 PDTOs included in the two cohorts were derived from mCRC primary tumors or metastases. The first cohort included 31 PDTOs derived from patients treated in front line. For this cohort, DSA results were matched with patient responses. Moreover, RAS/BRAF mutational status was matched with DSA cetuximab response. Ten out of 12 (83.3%) RAS wild-type PDTOs responded to cetuximab, while all the mutant PDTOs, 8 out of 8 (100%), were resistant. For the second cohort (chemorefractory patients), we used part of tumor tissue for genotyping. Four out of nine DSA/genotyping data resulted applicable in the clinic. Two RAS-mutant mCRC patients have been treated with FOLFOX-bevacizumab and mitomycin-capecitabine in third line, respectively, based on DSA results, obtaining disease control. One patient was treated with nivolumab-second mitochondrial-derived activator of caspases mimetic (phase I trial) due to high tumor mutational burden at genotyping, experiencing stable disease. In one case, the presence of BRCA2 mutation correlated with DSA sensitivity to olaparib; however, the patient could not receive the therapy. CONCLUSIONS Using CRC as a model, we have designed and validated a clinically applicable methodology to potentially inform clinical decisions with functional data. Undoubtedly, further larger analyses are needed to improve methodology success rates and propose suitable treatment strategies for mCRC patients.
Collapse
Affiliation(s)
- G Martini
- Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, Naples
| | - V Belli
- Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, Naples
| | - S Napolitano
- Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, Naples
| | - V Ciaramella
- Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, Naples
| | - D Ciardiello
- Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, Naples
| | - A Belli
- Hepatobiliary Surgical Oncology Unit, Istituto Nazionale Tumori-Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Fondazione G. Pascale, Napoli
| | - F Izzo
- Hepatobiliary Surgical Oncology Unit, Istituto Nazionale Tumori-Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Fondazione G. Pascale, Napoli
| | - A Avallone
- Experimental Clinical Abdominal Oncology Unit, Istituto Nazionale Tumori-Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Fondazione G. Pascale, Napoli
| | - F Selvaggi
- Department of Advanced Medical and Surgical Sciences, Università degli Studi della Campania Luigi Vanvitelli, Naples
| | - F Menegon Tasselli
- Department of Advanced Medical and Surgical Sciences, Università degli Studi della Campania Luigi Vanvitelli, Naples
| | - W Santaniello
- Hepatobiliary Surgical Oncology Unit, AORN Cardarelli, Naples
| | - R Franco
- Pathology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy
| | - I Puig
- Translational Program, Stem Cells and Cancer Laboratory, Vall D'Hebron Institute of Oncology (VHIO), Barcelona
| | - L Ramirez
- Translational Program, Stem Cells and Cancer Laboratory, Vall D'Hebron Institute of Oncology (VHIO), Barcelona
| | - I Chicote
- Translational Program, Stem Cells and Cancer Laboratory, Vall D'Hebron Institute of Oncology (VHIO), Barcelona
| | - F Mancuso
- Cancer Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona
| | - G Caratu
- Cancer Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona
| | - X Serres
- Department of Interventional Radiology, Hospital Universitari Vall d'Hebron, Barcelona
| | - R Fasani
- Molecular Oncology Lab, Vall d'Hebron Institute of Oncology, Barcelona
| | - J Jimenez
- Molecular Oncology Lab, Vall d'Hebron Institute of Oncology, Barcelona
| | - J Ros
- Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), Barcelona
| | - I Baraibar
- Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), Barcelona
| | - N Mulet
- B-ARGO Badalona Applied Research Group in Oncology, Catalan Institute of Oncology, Badalona
| | - C M Della Corte
- Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, Naples
| | - T Troiani
- Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, Naples
| | - A Vivancos
- Cancer Genomics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona
| | - R Dienstmann
- Oncology Data Science, Vall d'Hebron Institute of Oncology, Barcelona
| | - E Elez
- Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), Barcelona
| | - H G Palmer
- Translational Program, Stem Cells and Cancer Laboratory, Vall D'Hebron Institute of Oncology (VHIO), Barcelona
| | - J Tabernero
- Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), Barcelona
| | - E Martinelli
- Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, Naples
| | - F Ciardiello
- Department of Precision Medicine, Università degli Studi della Campania Luigi Vanvitelli, Naples
| | - G Argilés
- Vall d'Hebron Hospital Campus and Institute of Oncology (VHIO), Barcelona; Universitat Autònoma de Barcelona, Barcelona, Spain; Memorial Sloan Kettering Cancer Center, New York, USA.
| |
Collapse
|
12
|
de Almeida MP, Rodrigues C, Novais Â, Grosso F, Leopold N, Peixe L, Franco R, Pereira E. Silver Nanostar-Based SERS for the Discrimination of Clinically Relevant Acinetobacter baumannii and Klebsiella pneumoniae Species and Clones. Biosensors (Basel) 2023; 13:149. [PMID: 36831915 PMCID: PMC9953856 DOI: 10.3390/bios13020149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Subscribe] [Scholar Register] [Received: 12/20/2022] [Revised: 01/12/2023] [Accepted: 01/14/2023] [Indexed: 06/18/2023]
Abstract
The development of rapid, reliable, and low-cost methods that enable discrimination among clinically relevant bacteria is crucial, with emphasis on those listed as WHO Global Priority 1 Critical Pathogens, such as carbapenem-resistant Acinetobacter baumannii and carbapenem-resistant or ESBL-producing Klebsiella pneumoniae. To address this problem, we developed and validated a protocol of surface-enhanced Raman spectroscopy (SERS) with silver nanostars for the discrimination of A. baumannii and K. pneumoniae species, and their globally disseminated and clinically relevant antibiotic resistant clones. Isolates were characterized by mixing bacterial colonies with silver nanostars, followed by deposition on filter paper for SERS spectrum acquisition. Spectral data were processed with unsupervised and supervised multivariate data analysis methods, including principal component analysis (PCA) and partial least-squares discriminant analysis (PLSDA), respectively. Our proposed SERS procedure using silver nanostars adsorbed to the bacteria, followed by multivariate data analysis, enabled differentiation between and within species. This pilot study demonstrates the potential of SERS for the rapid discrimination of clinically relevant A. baumannii and K. pneumoniae species and clones, displaying several advantages such as the ease of silver nanostars synthesis and the possible use of a handheld spectrometer, which makes this approach ideal for point-of-care applications.
Collapse
Affiliation(s)
- Miguel Peixoto de Almeida
- LAQV/REQUIMTE, Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade do Porto, 4169-007 Porto, Portugal
| | - Carla Rodrigues
- UCIBIO—Applied Molecular Biosciences Unit, Department of Biological Sciences, Laboratory of Microbiology, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal
- Associate Laboratory, Institute for Health and Bioeconomy, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal
| | - Ângela Novais
- UCIBIO—Applied Molecular Biosciences Unit, Department of Biological Sciences, Laboratory of Microbiology, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal
- Associate Laboratory, Institute for Health and Bioeconomy, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal
- 4TOXRUN, Toxicology Research Unit, University Institute of Health Sciences, CESPU (IUCS-CESPU), 4585-116 Gandra, Portugal
| | - Filipa Grosso
- UCIBIO—Applied Molecular Biosciences Unit, Department of Biological Sciences, Laboratory of Microbiology, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal
- Associate Laboratory, Institute for Health and Bioeconomy, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal
| | - Nicolae Leopold
- Faculty of Physics, Babeş-Bolyai University, 400084 Cluj-Napoca, Romania
| | - Luísa Peixe
- UCIBIO—Applied Molecular Biosciences Unit, Department of Biological Sciences, Laboratory of Microbiology, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal
- Associate Laboratory, Institute for Health and Bioeconomy, Faculty of Pharmacy, University of Porto, 4050-313 Porto, Portugal
| | - Ricardo Franco
- Associate Laboratory i4HB—Institute for Health and Bioeconomy, School of Science and Technology, Universidade NOVA de Lisboa, 2819-516 Caparica, Portugal
- UCIBIO—Applied Molecular Biosciences Unit, Departamento de Química, School of Science and Technology, Universidade NOVA de Lisboa, 2819-516 Caparica, Portugal
| | - Eulália Pereira
- LAQV/REQUIMTE, Departamento de Química e Bioquímica, Faculdade de Ciências, Universidade do Porto, 4169-007 Porto, Portugal
| |
Collapse
|
13
|
Oliveira MJ, Dalot A, Fortunato E, Martins R, Byrne HJ, Franco R, Águas H. Microfluidic SERS devices: brightening the future of bioanalysis. Discov Mater 2022; 2:12. [PMID: 36536830 PMCID: PMC9751519 DOI: 10.1007/s43939-022-00033-3] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/20/2022] [Accepted: 11/29/2022] [Indexed: 06/17/2023]
Abstract
A new avenue has opened up for applications of surface-enhanced Raman spectroscopy (SERS) in the biomedical field, mainly due to the striking advantages offered by SERS tags. SERS tags provide indirect identification of analytes with rich and highly specific spectral fingerprint information, high sensitivity, and outstanding multiplexing potential, making them very useful in in vitro and in vivo assays. The recent and innovative advances in nanomaterial science, novel Raman reporters, and emerging bioconjugation protocols have helped develop ultra-bright SERS tags as powerful tools for multiplex SERS-based detection and diagnosis applications. Nevertheless, to translate SERS platforms to real-world problems, some challenges, especially for clinical applications, must be addressed. This review presents the current understanding of the factors influencing the quality of SERS tags and the strategies commonly employed to improve not only spectral quality but the specificity and reproducibility of the interaction of the analyte with the target ligand. It further explores some of the most common approaches which have emerged for coupling SERS with microfluidic technologies, for biomedical applications. The importance of understanding microfluidic production and characterisation to yield excellent device quality while ensuring high throughput production are emphasised and explored, after which, the challenges and approaches developed to fulfil the potential that SERS-based microfluidics have to offer are described.
Collapse
Affiliation(s)
- Maria João Oliveira
- CENIMAT|i3N, Department of Materials Science, School of Science and Technology, NOVA University Lisbon and, CEMOP/UNINOVA, Caparica, Portugal
- Associate Laboratory i4HB—Institute for Health and Bioeconomy, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, 2829-516 Caparica, Portugal
- UCIBIO—Applied Molecular Biosciences Unit, Departamento de Química, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, 2829-516 Caparica, Portugal
| | - Ana Dalot
- CENIMAT|i3N, Department of Materials Science, School of Science and Technology, NOVA University Lisbon and, CEMOP/UNINOVA, Caparica, Portugal
- Associate Laboratory i4HB—Institute for Health and Bioeconomy, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, 2829-516 Caparica, Portugal
- UCIBIO—Applied Molecular Biosciences Unit, Departamento de Química, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, 2829-516 Caparica, Portugal
| | - Elvira Fortunato
- CENIMAT|i3N, Department of Materials Science, School of Science and Technology, NOVA University Lisbon and, CEMOP/UNINOVA, Caparica, Portugal
| | - Rodrigo Martins
- CENIMAT|i3N, Department of Materials Science, School of Science and Technology, NOVA University Lisbon and, CEMOP/UNINOVA, Caparica, Portugal
| | - Hugh J. Byrne
- FOCAS Research Institute, Technological University Dublin, Camden Row, Dublin 8, Dublin, Ireland
| | - Ricardo Franco
- Associate Laboratory i4HB—Institute for Health and Bioeconomy, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, 2829-516 Caparica, Portugal
- UCIBIO—Applied Molecular Biosciences Unit, Departamento de Química, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, 2829-516 Caparica, Portugal
| | - Hugo Águas
- CENIMAT|i3N, Department of Materials Science, School of Science and Technology, NOVA University Lisbon and, CEMOP/UNINOVA, Caparica, Portugal
| |
Collapse
|
14
|
Anestopoulos I, Kyriakou S, Tragkola V, Paraskevaidis I, Tzika E, Mitsiogianni M, Deligiorgi MV, Petrakis G, Trafalis DT, Botaitis S, Giatromanolaki A, Koukourakis MI, Franco R, Pappa A, Panayiotidis MI. Targeting the epigenome in malignant melanoma: Facts, challenges and therapeutic promises. Pharmacol Ther 2022; 240:108301. [PMID: 36283453 DOI: 10.1016/j.pharmthera.2022.108301] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2022] [Revised: 10/03/2022] [Accepted: 10/19/2022] [Indexed: 11/16/2022]
Abstract
Malignant melanoma is the most lethal type of skin cancer with high rates of mortality. Although current treatment options provide a short-clinical benefit, acquired-drug resistance highlights the low 5-year survival rate among patients with advanced stage of the disease. In parallel, the involvement of an aberrant epigenetic landscape, (e.g., alterations in DNA methylation patterns, histone modifications marks and expression of non-coding RNAs), in addition to the genetic background, has been also associated with the onset and progression of melanoma. In this review article, we report on current therapeutic options in melanoma treatment with a focus on distinct epigenetic alterations and how their reversal, by specific drug compounds, can restore a normal phenotype. In particular, we concentrate on how single and/or combinatorial therapeutic approaches have utilized epigenetic drug compounds in being effective against malignant melanoma. Finally, the role of deregulated epigenetic mechanisms in promoting drug resistance to targeted therapies and immune checkpoint inhibitors is presented leading to the development of newly synthesized and/or improved drug compounds capable of targeting the epigenome of malignant melanoma.
Collapse
Affiliation(s)
- I Anestopoulos
- Department of Cancer Genetics, Therapeutics & Ultrastructural Pathology, The Cyprus Institute of Neurology & Genetics, Nicosia, Cyprus
| | - S Kyriakou
- Department of Cancer Genetics, Therapeutics & Ultrastructural Pathology, The Cyprus Institute of Neurology & Genetics, Nicosia, Cyprus
| | - V Tragkola
- Department of Cancer Genetics, Therapeutics & Ultrastructural Pathology, The Cyprus Institute of Neurology & Genetics, Nicosia, Cyprus
| | - I Paraskevaidis
- Department of Cancer Genetics, Therapeutics & Ultrastructural Pathology, The Cyprus Institute of Neurology & Genetics, Nicosia, Cyprus
| | - E Tzika
- Department of Cancer Genetics, Therapeutics & Ultrastructural Pathology, The Cyprus Institute of Neurology & Genetics, Nicosia, Cyprus
| | | | - M V Deligiorgi
- Laboratory of Pharmacology, Medical School, National & Kapodistrian University of Athens, Athens, Greece
| | - G Petrakis
- Saint George Hospital, Chania, Crete, Greece
| | - D T Trafalis
- Laboratory of Pharmacology, Medical School, National & Kapodistrian University of Athens, Athens, Greece
| | - S Botaitis
- Department of Surgery, Alexandroupolis University Hospital, Democritus University of Thrace School of Medicine, Alexandroupolis, Greece
| | - A Giatromanolaki
- Department of Pathology, Democritus University of Thrace, University General Hospital of Alexandroupolis, Alexandroupolis, Greece
| | - M I Koukourakis
- Radiotherapy / Oncology, Radiobiology & Radiopathology Unit, Department of Medicine, School of Health Sciences, Democritus University of Thrace, Alexandroupolis, Greece
| | - R Franco
- Redox Biology Centre, University of Nebraska-Lincoln, Lincoln, NE, USA; School of Veterinary Medicine & Biomedical Sciences, University of Nebraska-Lincoln, Lincoln, NE, USA
| | - A Pappa
- Department of Molecular Biology & Genetics, Democritus University of Thrace, Alexandroupolis, Greece
| | - M I Panayiotidis
- Department of Cancer Genetics, Therapeutics & Ultrastructural Pathology, The Cyprus Institute of Neurology & Genetics, Nicosia, Cyprus.
| |
Collapse
|
15
|
Reynolds L, Franco R, Prados M, Rodgers JB, Hand DT, Walter LA. Hepatitis C active viremia over time in an ED-based testing programme: Impact, disparities and surveillance tool. J Viral Hepat 2022; 29:1026-1034. [PMID: 36062383 DOI: 10.1111/jvh.13744] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/20/2022] [Revised: 08/17/2022] [Accepted: 08/20/2022] [Indexed: 12/09/2022]
Abstract
Hepatitis C virus (HCV) surveillance is a critical component of a comprehensive strategy to prevent and control HCV infection and HCV-related chronic liver disease. The emergency department (ED) has been increasingly recognized as a vital partner in HCV testing and linkage. We sought to consider active RNA HCV viremia over time in patients participating in an ED-based testing programme as a measure of local HCV surveillance and as a barometer of ED-testing programme impact. We performed a retrospective analysis of individuals participating in our ED-based HCV testing programme between 2015 and 2021. Chi-square tests were used to compare the demographic characteristics of HCV antibody positive tests with active viremia to those without active viremia. Cox proportional hazard models were used to estimate the trend in active viremia risk over time in the overall study population as well as in key subpopulations of interest. Of 5456 HCV antibody positive individuals, 3102 (56.8%) had active viremia. In the overall study population, we found that the risk of active viremia decreased by 4.8% per year during the study period (RR: 0.95, 95% CI: 0.93-0.97|p < .0001). Baby boomers experienced a 9% decrease in active viremia risk per year over the study period while non-baby boomers only had a 2% decrease in risk per year (p = .0009). Compared with insured patients, uninsured patients had a smaller decrease in risk of active HCV viremia per year (p = .003). No significant differences in the risk of active viremia over time were observed for gender (p = .4694) or by primary care provider status (p = .2208). In conclusion, this ED-based testing and linkage programme demonstrates significantly decreased active HCV viremia over time. It also highlights subpopulations, specifically non-baby boomers and uninsured patients, who may benefit from focused interventions to improve access to and adoption of definitive HCV care.
Collapse
Affiliation(s)
- Lindy Reynolds
- Department of Emergency Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA
| | - Ricardo Franco
- Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA
| | - Myles Prados
- Division of Infectious Diseases, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA
| | - Joel B Rodgers
- Division of Acute Care Surgery, Department of Surgery, University of Alabama at Birmingham, Birmingham, Alabama, USA
| | - Delissa T Hand
- O'Neal Comprehensive Cancer Center, University of Alabama at Birmingham, Birmingham, Alabama, USA
| | - Lauren A Walter
- Department of Emergency Medicine, University of Alabama at Birmingham, Birmingham, Alabama, USA
| |
Collapse
|
16
|
Basilicata M, Zarone F, Leone R, Guerriero C, Di Lauro M, Franco R, Bernardini S, Noce A, Bollero P, Sorrentino R. Impact of SARS-CoV-2 on dentistry: a review of literature. Eur Rev Med Pharmacol Sci 2022; 26:3386-3398. [PMID: 35587093 DOI: 10.26355/eurrev_202205_28760] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVE SARS-CoV-2 is a new Coronavirus identified as the cause of Coronavirus disease in 2019 (COVID-19). The epidemic spread in China and beyond its borders, involving 114 countries with more than 5 million dead. On March 11, the WHO declared the spread of SARS-CoV-2 to be a pandemic and encouraged nations to adopt harsh restrictive measures. Therefore, patients more and more often turn to dental offices only for emergencies. Healthcare professionals, including dentists, are at high infectious risk. In fact, the closeness to the oral cavity and nasopharynx and the use of drills or ultrasonic devices that cause aerosol release, make dental professions at high risk of bacterial and viral infections. The way patients are treated has changed. In fact, it should be mandatory to carry out a pre-treatment telephone triage and the use of mouthwashes to reduce bacterial load. In the current pandemic, it is necessary to adopt specific safety protocols that can protect dental operators as well as limit the spread of the virus. The purpose of this review is to present an overview on ways to reduce the risk of SARS-CoV-2 contagion in dentistry by focusing on the immediate situation as well as by looking towards the future. MATERIALS AND METHODS To reach the review purpose, we selected a series of studies using keywords "COVID-19" OR "SARS-CoV-2" in association with "dentistry" AND "safety protocols" AND "healthcare procedures" AND "individual protection dispositive" AND "air transmission" AND "droplet". We selected papers exclusively in English language, up to 1st January 2022. RESULTS During future phases of the pandemic, everywhere in the World, it is necessary to impose all dentistry team both a serological screening and the vaccination, as already established for all health staff in Italy. CONCLUSIONS For own safety, it is an important for the whole dentistry category constantly update the devices and the protocols adopted, as well as monitoring the real infectious threats, which may occur.
Collapse
Affiliation(s)
- M Basilicata
- Department of Experimental Medicine and Surgery, University of Rome "Tor Vergata", Rome, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
17
|
Kim HN, Nance RM, Lo Re V, Silverberg MJ, Franco R, Sterling TR, Cachay ER, Horberg MA, Althoff KN, Justice AC, Moore RD, Klein M, Crane HM, Delaney JA, Kitahata MM. Development and Validation of a Model for Prediction of End-Stage Liver Disease in People With HIV. J Acquir Immune Defic Syndr 2022; 89:396-404. [PMID: 35202048 PMCID: PMC8887786 DOI: 10.1097/qai.0000000000002886] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/30/2021] [Accepted: 12/06/2021] [Indexed: 11/26/2022]
Abstract
BACKGROUND End-stage liver disease (ESLD) is a leading cause of non-AIDS-related death among people with HIV (PWH). Factors that increase the progression of liver disease include comorbidities and HIV-specific factors, but we currently lack a tool to apply this evidence into clinical practice. METHODS We developed and validated a risk prediction model for ESLD among PWH who received care in 12 cohorts of the North American AIDS Cohort Collaboration on Research and Design between 2000 and 2016 and had fibrosis-4 index > 1.45. The first occurrence of ascites, variceal bleed, spontaneous bacterial peritonitis, or hepatic encephalopathy was verified by standardized medical record review. The Bayesian model averaging was used to select predictors among biomarkers and diagnoses and the Harrell C statistic to assess model discrimination. RESULTS Among 13,787 PWH in the training set, 82% were men and 54% were Black with a mean age of 48 years. Three hundred ninety ESLD events occurred over a mean 5.4 years. Among the ESLD cases, 52% had hepatitis C virus, 15% hepatitis B virus, and 31% alcohol use disorder. Twelve factors together predicted ESLD risk moderately well (C statistic 0.79, 95% confidence interval: 0.76 to 0.81): age, sex, race/ethnicity, chronic hepatitis B or C, and routinely collected laboratory values reflecting hepatic impairment (serum albumin, aspartate aminotransferase, total bilirubin, and platelets) and lipid metabolism (triglycerides, high-density lipoprotein, and total cholesterol). Our model performed well in the test set (C statistic 0.81, 95% confidence interval: 0.76 to 0.86). CONCLUSION This model of readily accessible clinical parameters predicted ESLD in a large diverse population of PWH.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | | | - Amy C. Justice
- Yale University Schools of Medicine and Public Health, New Haven, CT, USA and Veterans Administration Connecticut Healthcare System, USA
| | | | - Marina Klein
- McGill University Health Centre, Montreal, Quebec, Canada
| | | | - Joseph A. Delaney
- University of Washington, Seattle, WA, USA
- University of Manitoba, Winnipeg, Manitoba, Canada
| | | |
Collapse
|
18
|
Oliveira MJ, Cunha I, de Almeida MP, Calmeiro T, Fortunato E, Martins R, Pereira L, Byrne HJ, Pereira E, Águas H, Franco R. Reusable and highly sensitive SERS immunoassay utilizing gold nanostars and a cellulose hydrogel-based platform. J Mater Chem B 2021; 9:7516-7529. [PMID: 34551048 DOI: 10.1039/d1tb01404h] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/26/2022]
Abstract
The development of robust and sensitive point-of-care testing platforms is necessary to improve patient care and outcomes. Surface-enhanced Raman scattering (SERS)-based immunosensors are especially suited for this purpose. Here, we present a highly sensitive and selective SERS immunoassay, demonstrating for example the detection of horseradish peroxidase (HRP), in a sandwich format. The strength of our biosensor lies in merging: (i) SERS-immunotags based on gold nanostars, allowing exceptional intense SERS from attached Raman probes, covalent attachment of anti-HRP antibodies by a simple chemical method providing exceptional antigen binding activity; (ii) the ease of preparation of the capture platform from a regenerated cellulose-based hydrogel, a transparent material, ideal for microfluidics applications, with low background fluorescence and Raman signal, particularly suited for preserving high activity of the covalently bound anti-HRP antibodies. The sandwich complexes formed were characterised by atomic force microscopy, and by scanning electron microscopy coupled with electron diffraction spectroscopy; and (iii) the robustness of the simple Classical Least Squares method for SERS data analysis, resulting in superior discrimination of SERS signals from the background and much better data fitting, compared to the commonly used peak integral method. Our SERS immunoassay greatly improves the detection limits of traditional enzyme-linked immunosorbent assay approaches, and its performance is better or comparable to those of existing SERS-based immunosensors. Our approach successfully overcomes the main challenges of application at point-of-care, including increasing reproducibility, sensitivity, and specificity, associated with an environmentally friendly and robust design. Also, the proposed design withstands several cycles of regeneration, a feature absent in paper-SERS immunoassays and this opens the way for sensitive multiplexing applications on a microfluidic platform.
Collapse
Affiliation(s)
- Maria João Oliveira
- CENIMAT-i3N, Departamento de Ciência dos Materiais, Faculdade de Ciências e Tecnologia, FCT, Universidade Nova de Lisboa, 2829-516 Caparica, Portugal. .,Associate Laboratory i4HB, Institute for Health and Bioeconomy, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, 2829-516 Caparica, Portugal. .,UCIBIO, REQUIMTE, Departamento de Química, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, 2829-516 Caparica, Portugal
| | - Inês Cunha
- CENIMAT-i3N, Departamento de Ciência dos Materiais, Faculdade de Ciências e Tecnologia, FCT, Universidade Nova de Lisboa, 2829-516 Caparica, Portugal.
| | - Miguel P de Almeida
- REQUIMTE/LAQV, Departamento de Química e Bioquímica, Faculdade de Ciências da Universidade do Porto, 4169-007 Porto, Portugal.
| | - Tomás Calmeiro
- CENIMAT-i3N, Departamento de Ciência dos Materiais, Faculdade de Ciências e Tecnologia, FCT, Universidade Nova de Lisboa, 2829-516 Caparica, Portugal.
| | - Elvira Fortunato
- CENIMAT-i3N, Departamento de Ciência dos Materiais, Faculdade de Ciências e Tecnologia, FCT, Universidade Nova de Lisboa, 2829-516 Caparica, Portugal.
| | - Rodrigo Martins
- CENIMAT-i3N, Departamento de Ciência dos Materiais, Faculdade de Ciências e Tecnologia, FCT, Universidade Nova de Lisboa, 2829-516 Caparica, Portugal.
| | - Luís Pereira
- CENIMAT-i3N, Departamento de Ciência dos Materiais, Faculdade de Ciências e Tecnologia, FCT, Universidade Nova de Lisboa, 2829-516 Caparica, Portugal. .,AlmaScience, Campus da Caparica, 2829-516 Caparica, Portugal
| | - Hugh J Byrne
- FOCAS Research Institute, Technological University Dublin, Camden Street, Dublin 8, Ireland.
| | - Eulália Pereira
- REQUIMTE/LAQV, Departamento de Química e Bioquímica, Faculdade de Ciências da Universidade do Porto, 4169-007 Porto, Portugal.
| | - Hugo Águas
- CENIMAT-i3N, Departamento de Ciência dos Materiais, Faculdade de Ciências e Tecnologia, FCT, Universidade Nova de Lisboa, 2829-516 Caparica, Portugal.
| | - Ricardo Franco
- Associate Laboratory i4HB, Institute for Health and Bioeconomy, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, 2829-516 Caparica, Portugal. .,UCIBIO, REQUIMTE, Departamento de Química, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, 2829-516 Caparica, Portugal
| |
Collapse
|
19
|
Bushman ET, Subramani L, Sanjanwala A, Dionne-Odom J, Franco R, Owen J, Subramaniam A. Pragmatic Experience with Risk-based versus Universal Hepatitis C Screening in Pregnancy: Detection of Infection and Postpartum Linkage to Care. Am J Perinatol 2021; 38:1109-1116. [PMID: 33934324 DOI: 10.1055/s-0041-1728827] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
OBJECTIVE Despite the Centers for Disease Control and Prevention (CDC) and U.S. Preventive Services Task Force (USPSTF) recommending universal hepatitis C virus (HCV) screening in pregnancy Society for Maternal-Fetal Medicine (SMFM) and American College of Obstetricians and Gynecologists (ACOG) continue to endorse risk-based screening for HCV in pregnancy. We hypothesized that universal screening is associated with increased HCV diagnosis and postpartum linkage to HCV care compared with risk-based screening. STUDY DESIGN This retrospective cohort study included pregnant women screened for HCV at a single tertiary-care center. We defined two cohorts: women managed with risk-based (January 2014-October 2016) or universal HCV screening (November 2016-December 2018). Screening was performed with ELISA antibody testing and viremia confirmed with HCV ribonucleic acid (RNA) polymerase chain reaction (PCR). Primary outcomes were the rate of HCV screen positivity and postpartum linkage to care. RESULTS From 2014 to 2018, 16,489 women delivered at our institution, of whom 166 screened positive for HCV. A total of 7,039 pregnant women were screened for HCV: 266 with risk-based and 6,773 with universal screening; 29% (76/266) were positive HCV antibody screening (HCVAb + ) in the risk-based cohort and 1.3% (90/6,773) in the universal cohort. HCVAb+ women in the risk-based cohort were more likely to have a positive drug screen. Only 69% (62/90) of HCVAb+ women in the universal cohort met the criteria for risk-based testing. Of the remaining 28 women, 6 (21%) had active viremia (HCV RNA+). Of the 166 HCVAb+ women, 64% (103/166) were HCV RNA+-51 of 266 (19%) in the risk-based and 52 of 6,773 (0.8%) in the universal cohort. Of HCVAb+ women, 75% (125/166) were referred postpartum for HCV evaluation and 27% (34/125) were linked to care. Only 9% (10/103) of women with viremia initiated treatment within 1 year of delivery. CONCLUSION Universal HCV screening in pregnancy identified an additional 31% of HCVAb+ women compared with risk-based screening. Given low rates of HCV follow-up and treatment regardless of screening modality, further studies are needed to address barriers to postpartum linkage to care. KEY POINTS · Ideal screening for HCV in pregnancy is unknown.. · We explore screening strategies in pregnancy to linkage to HCV care.. · Regardless of screening strategy there is low rates of postpartum linkage to HCV care..
Collapse
Affiliation(s)
- Elisa T Bushman
- Center for Women's Reproductive Health, University of Alabama at Birmingham, Birmingham, Alabama.,Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, Alabama
| | - Lakshmi Subramani
- University of Alabama Birmingham School of Medicine, Birmingham, Alabama
| | - Aalok Sanjanwala
- Center for Women's Reproductive Health, University of Alabama at Birmingham, Birmingham, Alabama.,Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, Alabama
| | - Jodie Dionne-Odom
- Department of Medicine, University of Alabama Birmingham, Birmingham, Alabama
| | - Ricardo Franco
- Department of Medicine, University of Alabama Birmingham, Birmingham, Alabama
| | - John Owen
- Center for Women's Reproductive Health, University of Alabama at Birmingham, Birmingham, Alabama.,Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, Alabama
| | - Akila Subramaniam
- Center for Women's Reproductive Health, University of Alabama at Birmingham, Birmingham, Alabama.,Department of Obstetrics and Gynecology, University of Alabama at Birmingham, Birmingham, Alabama
| |
Collapse
|
20
|
Restrepo L, Murillo J, Botina D, Zarzycki A, Garzón J, Franco R, Montano J, Calderon S, Torres-Madronero MC, Marzani F, Robledo SM, Galeano J. Diffuse Reflectance Parameters of Treated Leishmaniasis Cutaneous Ulcers and Association with Histopathologies in an Animal Model: A Proof of Concept. SLAS Technol 2021; 26:667-680. [PMID: 34292085 DOI: 10.1177/24726303211030292] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Cutaneous leishmaniasis (CL) is a parasitic disease that produces chronic skin ulcers. Although it has a worldwide presence, it is a neglected disease that still requires novel tools for its management. In order to study the use of optical tools in CL, this article presents a preliminary study of the correlation between CL histopathological and optical parameters. Optical parameters correspond to absorption and scattering coefficients obtained from diffuse reflectance spectra of treated CL in golden hamsters. Independently, histopathological data were collected from the same hamsters. As a result, after Spearman correlation and the Kruskal-Wallis test, inverse correlation was found between absorption/scattering optical parameters and inflammatory histopathological values, such as the scattering parameter related to the diameter of fibroblasts with the histopathological parameters of fibrosis, polymorphonuclear neutrophils, lymphocytes, plasmocytes, hyperplasia, and Leishmania, and the absorption parameter oxygen saturation showed a relation with the granulation tissue histopathological parameter. These correlations agree with the expected behavior of tissue composition during the healing process in CL. The results correspond to a proof of concept that shows that optical diffuse reflectance-based tools and methods could be considered as an alternative to assist in CL diagnosis and treatment follow-up.
Collapse
Affiliation(s)
- Lina Restrepo
- Instituto Tecnológico Metropolitano, Medellín, Colombia
| | - Javier Murillo
- Program for the Study and Control of Tropical Diseases-PECET, School of Medicine, University of Antioquia, Medellín, Colombia
| | - Deivid Botina
- Research group on Advance Materials and Energy MatyEr, Biomaterials and Electromedicine Laboratory, Instituto Tecnológico Metropolitano, Medellín, Colombia.,Laboratoire ImViA, Université Bourgogne Franche-Comté, Dijon Cedex, France
| | - Artur Zarzycki
- Research group on Advance Materials and Energy MatyEr, Biomaterials and Electromedicine Laboratory, Instituto Tecnológico Metropolitano, Medellín, Colombia
| | - Johnson Garzón
- Grupo de Óptica y Espectroscopía, Centro de Ciencia Básica, Universidad Pontificia Bolivariana, Medellín, Colombia
| | - Ricardo Franco
- Research group on Automatic, Electronic and Computational Science, MIRP Laboratory, Instituto Tecnológico Metropolitano, Medellín, Colombia
| | - Jaime Montano
- Program for the Study and Control of Tropical Diseases-PECET, School of Medicine, University of Antioquia, Medellín, Colombia
| | - Samuel Calderon
- Program for the Study and Control of Tropical Diseases-PECET, School of Medicine, University of Antioquia, Medellín, Colombia
| | - Maria C Torres-Madronero
- Research group on Automatic, Electronic and Computational Science, MIRP Laboratory, Instituto Tecnológico Metropolitano, Medellín, Colombia
| | - Franck Marzani
- Laboratoire ImViA, Université Bourgogne Franche-Comté, Dijon Cedex, France
| | - Sara M Robledo
- Program for the Study and Control of Tropical Diseases-PECET, School of Medicine, University of Antioquia, Medellín, Colombia
| | - July Galeano
- Research group on Advance Materials and Energy MatyEr, Biomaterials and Electromedicine Laboratory, Instituto Tecnológico Metropolitano, Medellín, Colombia
| |
Collapse
|
21
|
French AL, Grennan D, Daubert E, Seaberg EC, Peters M, Augenbraun M, Fischl M, Kassaye S, Franco R, Kuniholm M, Adimora AA, Workowski K, Weber KM. Decreases in markers of monocyte/macrophage activation after hepatitis C eradication in HIV/hepatitis C virus coinfected women. AIDS 2021; 35:1433-1438. [PMID: 33710024 PMCID: PMC8845487 DOI: 10.1097/qad.0000000000002869] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
OBJECTIVE Eradication of hepatitis C virus (HCV) in HIV disease decreases liver and non-liver-related morbidity and mortality. Elevated markers of monocyte/macrophage activation (soluble CD163 and sCD14) are associated with excess non-AIDS morbidity and mortality in HIV. We examined the effect of HCV eradication on these markers in relation to change in hepatic fibrosis. DESIGN A nested substudy within a longitudinal observational cohort. METHODS We studied 126 HIV/HCV-coinfected women successfully treated for HCV, with undetectable HCV RNA at least 12 weeks after therapy completion. sCD163 and sCD14 were measured in serum collected before and after HCV eradication. Results were correlated with changes in markers of hepatic fibrosis. RESULTS Mean age of participants was 56.3 years, mean CD4+ cell count was 615, and 72% had suppressed HIV RNA. After treatment, sCD163 and sCD14 levels significantly decreased from pre-treatment levels in unadjusted analyses. After adjusting for age, race, hepatic fibrosis status, baseline HCV RNA, CD4 count and HIV RNA status, cigarette smoking, and alcohol use, the decreases in sCD163 and sCD14 remained significant. Decrease in pre-treatment to post-treatment sCD163 were significantly positively correlated with changes in FIB-4 (r = 0.250, P = 0.005) and APRI (r = 0.262, P = 0.003); similarly decrease in sCD14 was significantly positively correlated with changes in FIB-4 (r = 0.333, P = 0.0001) and APRI (r = 0.457, P < 0.0001). CONCLUSION HCV eradication is associated with significant reductions in monocyte/macrophage activation markers that correlate with reductions in markers of hepatic fibrosis. These findings support broad access to and early initiation of HCV treatment in order to decrease immune activation and improve health in HIV-infected persons.
Collapse
Affiliation(s)
- Audrey L French
- Division of Infectious Diseases, Stroger Hospital of Cook County Heath
| | - Dara Grennan
- Division of Infectious Diseases, Stroger Hospital of Cook County Heath
| | - Elizabeth Daubert
- Cook County Health and Hektoen Institute of Medicine, Chicago, Illinois
| | - Eric C Seaberg
- Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland
| | - Marion Peters
- Department of Medicine, Northwestern University, Chicago, Illinois
| | - Michael Augenbraun
- Department of Medicine, State University of New York Downstate Medical Center, Brooklyn, New York
| | - Margaret Fischl
- Division of Infectious Diseases, University of Miami Miller School of Medicine, Miami, Florida
| | - Seble Kassaye
- Division of Infectious Diseases, Georgetown University Medical Center, Washington, District of Columbia
| | - Ricardo Franco
- Division of Infectious Diseases, University of Alabama at Birmingham, Birmingham, Alabama
| | - Mark Kuniholm
- Department of Epidemiology and Biostatistics, University at Albany, State University of New York, Rensselaer, New York
| | - Adaora A Adimora
- Institute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina
| | | | - Kathleen M Weber
- Cook County Health and Hektoen Institute of Medicine, Chicago, Illinois
| |
Collapse
|
22
|
Panarese I, Pagliuca F, Ronchi A, Cozzolino I, Montella M, D'Abbronzo G, La Mantia E, Franco R, Berretta M. Intestinal, intestinal-type and intestine-localized metastatic adenocarcinoma. Immunohistochemical approach to the differential diagnosis. Eur Rev Med Pharmacol Sci 2021; 24:12171-12186. [PMID: 33336735 DOI: 10.26355/eurrev_202012_24006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
The pathologist is often called to define the origin of tumors through the help of ancillary studies, mainly immunohistochemical stainings. In this setting, the differential diagnosis between intestinal adenocarcinomas, other tumors with intestinal-type morphology, and adenocarcinomas metastatic to the bowel can be particularly difficult. In such cases, an accurate assessment of the disease is required to address the patients to the optimal treatment. Immunohistochemistry offers the use of multiple antibodies: the integrated evaluation of specific stainings can lead to a correct diagnosis. Particularly, the use of cytokeratins, mucins, and β-catenin could be of great help in most cases. In addition, recently, novel specific markers such as SATB2 and AMACR have been introduced, improving the utility of immunohistochemistry in the differential diagnosis of intestinal-type and intestinal adenocarcinomas.
Collapse
Affiliation(s)
- I Panarese
- Pathology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy.
| | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Franco R, Barlattani A, Perrone MA, Basili M, Miranda M, Costacurta M, Gualtieri P, Pujia A, Merra G, Bollero P. Obesity, bariatric surgery and periodontal disease: a literature update. Eur Rev Med Pharmacol Sci 2021; 24:5036-5045. [PMID: 32432767 DOI: 10.26355/eurrev_202005_21196] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Obesity is linked to other systemic diseases, such as diabetes mellitus, dyslipidemia, and arterial hypertension. These comorbidities increase the risk of developing cardiovascular disease risk. Adipose tissue is a true endocrine organ and releases various pro-inflammatory cytokines. Periodontal disease (PD) is a chronic inflammatory disorder of the gingiva and bone support (periodontal tissues) that surrounds the teeth. The relationship between obesity and an increased risk of developing PD is already known in the literature. Many studies correlated the cardiometabolic risk with periodontal disease. Bariatric surgery is a way to reduce the adipose tissue in obese patients, that meet specific criteria. It has been observed that this type of surgery usually reduces both the systemic inflammation and the cardiometabolic risk. Some authors have hypothesized that, as a result, the progression of periodontal disease is also reduced. Five articles are analyzed in this systematic review. In these papers, the periodontal health before and after the bariatric surgery was compared. However, the conclusion of the previous studies demonstrated a scarce literature and did not confirm the reduction of periodontal disease after bariatric surgery, but a reduction of cardiometabolic risk. Therefore, periodontal disease in no way influences the reduction of cardiovascular risk after bariatric surgery.
Collapse
Affiliation(s)
- R Franco
- Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
24
|
Ronchi A, Montella M, Cozzolino I, Argenziano G, Moscarella E, Piccolo V, Iovino F, Troiani T, Alfano R, Errico ME, D'Onofrio V, Berretta M, Franco R, Zito Marino F. The potential diagnostic and predictive role of anaplastic lymphoma kinase (ALK) gene alterations in melanocytic tumors. Eur Rev Med Pharmacol Sci 2021; 24:3829-3838. [PMID: 32329859 DOI: 10.26355/eurrev_202004_20849] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVE Anaplastic lymphoma kinase (ALK) gene has been demonstrated to be rearranged, mutated or amplified in several haematological and solid tumors. Moreover, the use of ALK inhibitors has recently revolutionized the treatment of ALK-rearranged patients affected by non-small cell lung carcinoma. Herein we review the genetic alterations of ALK in melanocytic neoplasms described in literature, focusing on their potential diagnostic and predictive role. MATERIALS AND METHODS The Authors reviewed the pertinent literature through research on PubMed server was performed typing the terms "ALK", "Anaplastic lymphoma kinase", "ALKATI", "Melanoma", "Spitz", "Spitzoid". RESULTS ALK translocations were demonstrated in melanocytic neoplasms, particularly in acral melanoma and spitzoid tumors. ALKATI was described in primary and metastatic melanoma, indicating its early occurrence in oncogenesis, with varying immunohistochemical expression of the protein. CONCLUSIONS The identification of the specific type of ALK mutations could be interesting for planning biologic therapy of melanoma patients. Further studies are needed to evaluate the possibility to introduce an ALK-targeted therapy in patients affected by malignant melanoma.
Collapse
Affiliation(s)
- A Ronchi
- Pathology Unit, Department of Mental and Physical Health and Preventive Medicine, University of Campania "L. Vanvitelli", Naples, Italy.
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
25
|
D'Abbronzo G, Franco R. Letter to the Editor: LINC01198 promotes colorectal cancer cell proliferation and inhibits apoptosis via Notch signaling pathway. Eur Rev Med Pharmacol Sci 2021; 24:9776-9777. [PMID: 33090450 DOI: 10.26355/eurrev_202010_23182] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- G D'Abbronzo
- Pathology Unit, Department of Mental and Physical Health and Preventive Medicine, Università degli Studi della Campania 'Luigi Vanvitelli', Naples, Italy
| | | |
Collapse
|
26
|
Toni G, Franco R, Di Francia R. Current predictive pathology in the clinical setting of colorectal cancer. Eur Rev Med Pharmacol Sci 2021; 24:481-482. [PMID: 32016948 DOI: 10.26355/eurrev_202001_20020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- G Toni
- Department of Mental and Physical Health and Preventive Medicine, Università degli Studi della Campania "Luigi Vanvitelli", Naples, Italy.
| | | | | |
Collapse
|
27
|
Saraga D, Maggos T, Degrendele C, Klánová J, Horvat M, Kocman D, Kanduč T, Garcia Dos Santos S, Franco R, Gómez PM, Manousakas M, Bairachtari K, Eleftheriadis K, Kermenidou M, Karakitsios S, Gotti A, Sarigiannis D. Multi-city comparative PM 2.5 source apportionment for fifteen sites in Europe: The ICARUS project. Sci Total Environ 2021; 751:141855. [PMID: 32889477 DOI: 10.1016/j.scitotenv.2020.141855] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/25/2020] [Revised: 08/01/2020] [Accepted: 08/19/2020] [Indexed: 06/11/2023]
Abstract
PM2.5 is an air pollution metric widely used to assess air quality, with the European Union having set targets for reduction in PM2.5 levels and population exposure. A major challenge for the scientific community is to identify, quantify and characterize the sources of atmospheric particles in the aspect of proposing effective control strategies. In the frame of ICARUS EU2020 project, a comprehensive database including PM2.5 concentration and chemical composition (ions, metals, organic/elemental carbon, Polycyclic Aromatic Hydrocarbons) from three sites (traffic, urban background, rural) of five European cities (Athens, Brno, Ljubljana, Madrid, Thessaloniki) was created. The common and synchronous sampling (two seasons involved) and analysis procedure offered the prospect of a harmonized Positive Matrix Factorization model approach, with the scope of identifying the similarities and differences of PM2.5 key-source chemical fingerprints across the sampling sites. The results indicated that the average contribution of traffic exhausts to PM2.5 concentration was 23.3% (traffic sites), 13.3% (urban background sites) and 8.8% (rural sites). The average contribution of traffic non-exhausts was 12.6% (traffic), 13.5% (urban background) and 6.1% (rural sites). The contribution of fuel oil combustion was 3.8% at traffic, 11.6% at urban background and 18.7% at rural sites. Biomass burning contribution was 22% at traffic sites, 30% at urban background sites and 28% at rural sites. Regarding soil dust, the average contribution was 5% and 8% at traffic and urban background sites respectively and 16% at rural sites. Sea salt contribution was low (1-4%) while secondary aerosols corresponded to the 16-34% of PM2.5. The homogeneity of the chemical profiles as well as their relationship with prevailing meteorological parameters were investigated. The results showed that fuel oil combustion, traffic non-exhausts and soil dust profiles are considered as dissimilar while biomass burning, sea salt and traffic exhaust can be characterized as relatively homogenous among the sites.
Collapse
Affiliation(s)
- D Saraga
- National Centre for Scientific Research 'Demokritos', Atmospheric Chemistry & Innovative Technologies Laboratory, 15310 Aghia Paraskevi, Athens, Greece.
| | - T Maggos
- National Centre for Scientific Research 'Demokritos', Atmospheric Chemistry & Innovative Technologies Laboratory, 15310 Aghia Paraskevi, Athens, Greece
| | - C Degrendele
- Masaryk University, RECETOX Centre, Kamenice 5, 625 00 Brno, Czech Republic
| | - J Klánová
- Masaryk University, RECETOX Centre, Kamenice 5, 625 00 Brno, Czech Republic
| | - M Horvat
- Department of Environmental Sciences, Jožef Stefan Institute, Jamova 39, 1000 Ljubljana, Slovenia
| | - D Kocman
- Department of Environmental Sciences, Jožef Stefan Institute, Jamova 39, 1000 Ljubljana, Slovenia
| | - T Kanduč
- Department of Environmental Sciences, Jožef Stefan Institute, Jamova 39, 1000 Ljubljana, Slovenia
| | - S Garcia Dos Santos
- Instituto de salud Carlos III, Área de Contaminación Atmosférica, Centro Nacional de Sanidad Ambiental, Ctra. Majadahonda a Pozuelo, 28220 Majadahonda, Madrid, Spain
| | - R Franco
- Instituto de salud Carlos III, Área de Contaminación Atmosférica, Centro Nacional de Sanidad Ambiental, Ctra. Majadahonda a Pozuelo, 28220 Majadahonda, Madrid, Spain
| | - P Morillo Gómez
- Instituto de salud Carlos III, Área de Contaminación Atmosférica, Centro Nacional de Sanidad Ambiental, Ctra. Majadahonda a Pozuelo, 28220 Majadahonda, Madrid, Spain
| | - M Manousakas
- National Centre for Scientific Research 'Demokritos', Environmental Radioactivity Laboratory, 15310 Aghia Paraskevi, Athens, Greece
| | - K Bairachtari
- National Centre for Scientific Research 'Demokritos', Atmospheric Chemistry & Innovative Technologies Laboratory, 15310 Aghia Paraskevi, Athens, Greece
| | - K Eleftheriadis
- National Centre for Scientific Research 'Demokritos', Environmental Radioactivity Laboratory, 15310 Aghia Paraskevi, Athens, Greece
| | - M Kermenidou
- Department of Chemical Engineering, Aristotle University of Thessaloniki (AUTH), Environmental Engineering Laboratory, 54124 Thessaloniki, Greece
| | - S Karakitsios
- Department of Chemical Engineering, Aristotle University of Thessaloniki (AUTH), Environmental Engineering Laboratory, 54124 Thessaloniki, Greece
| | - A Gotti
- Department of Chemical Engineering, Aristotle University of Thessaloniki (AUTH), Environmental Engineering Laboratory, 54124 Thessaloniki, Greece
| | - D Sarigiannis
- Department of Chemical Engineering, Aristotle University of Thessaloniki (AUTH), Environmental Engineering Laboratory, 54124 Thessaloniki, Greece
| |
Collapse
|
28
|
Franco R, Leandro D, Aurélio KM, Junior GDC, Marta G. PO-0811: Influence of time between surgery and postoperative radiation therapy in head and neck cancer. Radiother Oncol 2020. [DOI: 10.1016/s0167-8140(21)00828-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
29
|
Berretta M, Cobellis G, Franco R, Panarese I, Rinaldi B, Nasti G, Di Francia R, Rinaldi L. Features of microvessel density (MVD) and angiogenesis inhibitors in therapeutic approach of hepatocellular carcinoma (HCC). Eur Rev Med Pharmacol Sci 2020; 23:10139-10150. [PMID: 31799686 DOI: 10.26355/eurrev_201911_19584] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVE The curative hepatocellular carcinoma (HCC) therapy was traditionally based on surgical or loco-regional ablation approach. However, HCC is a solid tumor characterized by a highest level of vascularization; therefore, angiogenesis inhibitor could play a pivotal role in the pharmacological therapeutic approach. Despite the low number of approved drugs, a wide range of multi-kinase and MET inhibitor is currently being evaluated in phase II and III study. In this review, we described all the drugs that have shown efficacy in recently and ongoing trials. Moreover, the immunotherapy represents a recent challenge in the HCC treatment. The strategy based on the production of multi-epitope, multi-HLA peptide vaccine naturally processed and presented on primary tumor tissues of HCC patients. A further upgrade of cancer vaccine could be represented by the combination of metronomic chemotherapy and checkpoint inhibitors.
Collapse
Affiliation(s)
- M Berretta
- Department of Medical Oncology, Centro di Riferimento Oncologico, Istituto Nazionale Tumori "CRO", IRCCS Aviano (PN), Italy.
| | | | | | | | | | | | | | | |
Collapse
|
30
|
Diana A, Iovino F, Carlino F, Perrone A, Trovato C, Vassallo I, Antoniol G, Caraglia M, Franco R, Ciardiello F, Orditura M. 183P Prognostic value of high mesenchymal-epithelial transition factor gene (MET) expression in patients with estrogen receptor positive (ER+), human epidermal growth factor receptor negative (HER2-) early breast cancer. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.305] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
31
|
Rauso R, Colella G, Franco R, Chirico F, Ronchi A, Federico F, Volpicelli A, Tartaro G. Is hyaluronidase able to reverse embolism associated with hyaluronic acid filler? An anatomical case study. J BIOL REG HOMEOS AG 2020; 33:1927-1930. [PMID: 31960660 DOI: 10.23812/19-397-l] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- R Rauso
- Maxillo-Facial Surgery Unit, University of Campania "Luigi Vanvitelli", Naples, Italy
| | - G Colella
- Maxillo-Facial Surgery Unit, University of Campania "Luigi Vanvitelli", Naples, Italy
| | - R Franco
- Pathological Anatomy Department, University of Campania "Luigi Vanvitelli", Naples, Italy
| | - F Chirico
- Maxillo-Facial Surgery Unit, University of Campania "Luigi Vanvitelli", Naples, Italy
| | - A Ronchi
- Pathological Anatomy Department, University of Campania "Luigi Vanvitelli", Naples, Italy
| | - F Federico
- University of Campania "Luigi Vanvitelli", Naples, Italy
| | - A Volpicelli
- University of Campania "Luigi Vanvitelli", Naples, Italy
| | - G Tartaro
- Maxillo-Facial Surgery Unit, University of Campania "Luigi Vanvitelli", Naples, Italy
| |
Collapse
|
32
|
Lathouwers E, Wong EY, Brown K, Baugh B, Ghys A, Jezorwski J, Mohsine EG, Van Landuyt E, Opsomer M, De Meyer S, De Wit S, Florence E, Vandekerckhove L, Vandercam B, Brunetta J, Klein M, Murphy D, Rachlis A, Walmsley S, Ajana F, Cotte L, Girard PM, Katlama C, Molina JM, Poizot-Martin I, Raffi F, Rey D, Reynes J, Teicher E, Yazdanpanah Y, Arastéh K, Bickel M, Bogner J, Esser S, Faetkenheuer G, Jessen H, Kern W, Rockstroh J, Spinner C, Stellbrink HJ, Stoehr A, Antinori A, Castelli F, Chirianni A, De Luca A, Di Biagio A, Galli M, Lazzarin A, Maggiolo F, Maserati R, Mussini C, Garlicki A, Gasiorowski J, Halota W, Horban A, Parczewski M, Piekarska A, Belonosova E, Chernova O, Dushkina N, Kulagin V, Ryamova E, Shuldyakov A, Sizova N, Tsybakova O, Voronin E, Yakovlev A, Antela A, Arribas JR, Berenguer J, Casado J, Estrada V, Galindo MJ, Garcia Del Toro M, Gatell JM, Gorgolas M, Gutierrez F, Gutierrez MDM, Negredo E, Pineda JA, Podzamczer D, Portilla Sogorb J, Rivero A, Rubio R, Viciana P, De Los Santos I, Clarke A, Gazzard BG, Johnson MA, Orkin C, Reeves I, Waters L, Benson P, Bhatti L, Bredeek F, Crofoot G, Cunningham D, DeJesus E, Eron J, Felizarta F, Franco R, Gallant J, Hagins D, Henry K, Jayaweera D, Lucasti C, Martorell C, McDonald C, McGowan J, Mills A, Morales-Ramirez J, Prelutsky D, Ramgopal M, Rashbaum B, Ruane P, Slim J, Wilkin A, deVente J, De Wit S, Florence E, Moutschen M, Van Wijngaerden E, Vandekerckhove L, Vandercam B, Brunetta J, Conway B, Klein M, Murphy D, Rachlis A, Shafran S, Walmsley S, Ajana F, Cotte L, Girard PM, Katlama C, Molina JM, Poizot-Martin I, Raffi F, Rey D, Reynes J, Teicher E, Yazdanpanah Y, Gasiorowski J, Halota W, Horban A, Piekarska A, Witor A, Arribas JR, Perez-Valero I, Berenguer J, Casado J, Gatell JM, Gutierrez F, Galindo MJ, Gutierrez MDM, Iribarren JA, Knobel H, Negredo E, Pineda JA, Podzamczer D, Portilla Sogorb J, Pulido F, Ricart C, Rivero A, Santos Gil I, Blaxhult A, Flamholc L, Gisslèn M, Thalme A, Fehr J, Rauch A, Stoeckle M, Clarke A, Gazzard BG, Johnson MA, Orkin C, Post F, Ustianowski A, Waters L, Bailey J, Benson P, Bhatti L, Brar I, Bredeek UF, Brinson C, Crofoot G, Cunningham D, DeJesus E, Dietz C, Dretler R, Eron J, Felizarta F, Fichtenbaum C, Gallant J, Gathe J, Hagins D, Henn S, Henry KW, Huhn G, Jain M, Lucasti C, Martorell C, McDonald C, Mills A, Morales-Ramirez J, Mounzer K, Nahass R, Olivet H, Osiyemi O, Prelutsky D, Ramgopal M, Rashbaum B, Richmond G, Ruane P, Scarsella A, Scribner A, Shalit P, Shamblaw D, Slim J, Tashima K, Voskuhl G, Ward D, Wilkin A, de Vente J. Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials. AIDS Res Hum Retroviruses 2020; 36:48-57. [PMID: 31516033 PMCID: PMC6944133 DOI: 10.1089/aid.2019.0111] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg is being investigated in two Phase III trials, AMBER (NCT02431247; treatment-naive adults) and EMERALD (NCT02269917; treatment-experienced, virologically suppressed adults). Week 48 AMBER and EMERALD resistance analyses are presented. Postbaseline samples for genotyping/phenotyping were analyzed from protocol-defined virologic failures (PDVFs) with viral load (VL) ≥400 copies/mL at failure/later time points. Post hoc analyses were deep sequencing in AMBER, and HIV-1 proviral DNA from baseline samples (VL <50 copies/mL) in EMERALD. Through week 48 across both studies, no darunavir, primary PI, or tenofovir resistance-associated mutations (RAMs) were observed in HIV-1 viruses of 1,125 participants receiving D/C/F/TAF or 629 receiving boosted darunavir plus emtricitabine/tenofovir-disoproxil-fumarate. In AMBER, the nucleos(t)ide analog reverse transcriptase inhibitor (N(t)RTI) RAM M184I/V was identified in HIV-1 of one participant during D/C/F/TAF treatment. M184V was detected pretreatment as a minority variant (9%). In EMERALD, in participants with prior VF and genoarchive data (N = 140; 98 D/C/F/TAF and 42 control), 4% had viruses with darunavir RAMs, 38% with emtricitabine RAMs, mainly at position 184 (41% not fully susceptible to emtricitabine), 4% with tenofovir RAMs, and 21% ≥ 3 thymidine analog-associated mutations (24% not fully susceptible to tenofovir) detected at screening. All achieved VL <50 copies/mL at week 48 or prior discontinuation. D/C/F/TAF has a high genetic barrier to resistance; no darunavir, primary PI, or tenofovir RAMs were observed through 48 weeks in AMBER and EMERALD. Only one postbaseline M184I/V RAM was observed in HIV-1 of an AMBER participant. In EMERALD, baseline archived RAMs to darunavir, emtricitabine, and tenofovir in participants with prior VF did not preclude virologic response.
Collapse
Affiliation(s)
| | - Eric Y Wong
- Janssen Scientific Affairs, LLC, Titusville, New Jersey
| | | | - Bryan Baugh
- Janssen Research & Development LLC, Raritan, New Jersey
| | - Anne Ghys
- Janssen Pharmaceutica NV, Beerse, Belgium
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Bushman ET, Subramani L, Sanjanwala AR, Odom JD, Franco R, Owen J, Subramaniam A. 1050: Are sociodemographic and pregnancy characteristics associated with postpartum treatment of hepatitis C? Am J Obstet Gynecol 2020. [DOI: 10.1016/j.ajog.2019.11.1064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
34
|
Bushman ET, Subramani L, Sanjanwala AR, Odom JD, Franco R, Owen J, Subramaniam A. 777: A comparison of universal and risk-based screening for Hepatitis C in pregnancy. Am J Obstet Gynecol 2020. [DOI: 10.1016/j.ajog.2019.11.793] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
35
|
Tomás AL, de Almeida MP, Cardoso F, Pinto M, Pereira E, Franco R, Matos O. Development of a Gold Nanoparticle-Based Lateral-Flow Immunoassay for Pneumocystis Pneumonia Serological Diagnosis at Point-of-Care. Front Microbiol 2019; 10:2917. [PMID: 31921081 PMCID: PMC6931265 DOI: 10.3389/fmicb.2019.02917] [Citation(s) in RCA: 22] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/04/2019] [Accepted: 12/03/2019] [Indexed: 12/29/2022] Open
Abstract
Pneumocystis jirovecii pneumonia (PcP) is a major human immunodeficiency virus (HIV)-related illness, rising among immunocompromised non-HIV patients and in developing countries. Presently, the diagnosis requires respiratory specimens obtained through invasive and costly techniques that are difficult to perform in all patients or implement in all economic settings. Therefore, the development of a faster, cost-effective, non-invasive and field-friendly test to diagnose PcP would be a significant advance. In this study, recombinant synthetic antigens (RSA) of P. jirovecii's major surface glycoprotein (Msg) and kexin-like serine protease (Kex1) were produced and purified. These RSA were applied as antigenic tools in immunoenzymatic assays for detection of specific anti-P. jirovecii antibodies (IgG and IgM) in sera of patients with (n = 48) and without (n = 28) PcP. Results showed that only IgM anti-P. jirovecii levels were significantly increased in patients with PcP compared with patients without P. jirovecii infection (p ≤ 0.001 with both RSA). Thus, two strip lateral flow immunoassays (LFIA), based on the detection of specific IgM anti-P. jirovecii antibodies in human sera samples, were developed using the innovative association of P. jirovecii's RSA with spherical gold nanoparticles (AuNPs). For that, alkanethiol-functionalized spherical AuNPs with ca. ~40 nm in diameter were synthetized and conjugated with the two RSA (Msg or Kex1) produced. These AuNP-RSA conjugates were characterized by agarose gel electrophoresis (AGE) and optimized to improve their ability to interact specifically with serum IgM anti-P. jirovecii antibodies. Finally, two LFIA prototypes were developed and tested with pools of sera from patients with (positive sample) and without (negative sample) PcP. Both LFIA had the expected performance, namely, the presence of a test and control red colored lines with the positive sample, and only a control red colored line with the negative sample. These results provide valuable insights into the possibility of PcP serodiagnosis at point-of-care. The optimization, validation and implementation of this strip-based approach may help to reduce the high cost of medical diagnosis and subsequent treatment of PcP both in industrialized and low-income regions, helping to manage the disease all around the world.
Collapse
Affiliation(s)
- Ana Luísa Tomás
- Medical Parasitology Unit, Group of Opportunistic Protozoa/HIV and Other Protozoa, Global Health and Tropical Medicine, Instituto de Higiene e Medicina Tropical, Universidade NOVA de Lisboa, Lisbon, Portugal.,UCIBIO, REQUIMTE, Departamento de Química, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, Caparica, Portugal
| | - Miguel P de Almeida
- REQUIMTE/LAQV, Departamento de Química e Bioquímica, Faculdade de Ciências da Universidade do Porto, Porto, Portugal
| | - Fernando Cardoso
- Medical Parasitology Unit, Group of Opportunistic Protozoa/HIV and Other Protozoa, Global Health and Tropical Medicine, Instituto de Higiene e Medicina Tropical, Universidade NOVA de Lisboa, Lisbon, Portugal
| | - Mafalda Pinto
- UCIBIO, REQUIMTE, Departamento de Química, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, Caparica, Portugal
| | - Eulália Pereira
- REQUIMTE/LAQV, Departamento de Química e Bioquímica, Faculdade de Ciências da Universidade do Porto, Porto, Portugal
| | - Ricardo Franco
- UCIBIO, REQUIMTE, Departamento de Química, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, Caparica, Portugal
| | - Olga Matos
- Medical Parasitology Unit, Group of Opportunistic Protozoa/HIV and Other Protozoa, Global Health and Tropical Medicine, Instituto de Higiene e Medicina Tropical, Universidade NOVA de Lisboa, Lisbon, Portugal
| |
Collapse
|
36
|
Oliveira MJ, P de Almeida M, Nunes D, Fortunato E, Martins R, Pereira E, J Byrne H, Águas H, Franco R. Design and Simple Assembly of Gold Nanostar Bioconjugates for Surface-Enhanced Raman Spectroscopy Immunoassays. Nanomaterials (Basel) 2019; 9:nano9111561. [PMID: 31689919 PMCID: PMC6915668 DOI: 10.3390/nano9111561] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/15/2019] [Revised: 10/24/2019] [Accepted: 10/30/2019] [Indexed: 01/15/2023]
Abstract
Immunoassays using Surface-Enhanced Raman Spectroscopy are especially interesting on account not only of their increased sensitivity, but also due to its easy translation to point-of-care formats. The bases for these assays are bioconjugates of polyclonal antibodies and anisotropic gold nanoparticles functionalized with a Raman reporter. These bioconjugates, once loaded with the antigen analyte, can react on a sandwich format with the same antibodies immobilized on a surface. This surface can then be used for detection, on a microfluidics or immunochromatographic platform. Here, we have assembled bioconjugates of gold nanostars functionalized with 4-mercaptobenzoic acid, and anti-horseradish peroxidase antibodies. The assembly was by simple incubation, and agarose gel electrophoresis determined a high gold nanostar to antibody binding constant. The functionality of the bioconjugates is easy to determine since the respective antigen presents peroxidase enzymatic activity. Furthermore, the chosen antibody is a generic immunoglobulin G (IgG) antibody, opening the application of these principles to other antibody-antigen systems. Surface-Enhanced Raman Spectroscopy analysis of these bioconjugates indicated antigen detection down to 50 µU of peroxidase activity. All steps of conjugation were fully characterized by ultraviolet-visible spectroscopy, dynamic light scattering, ζ -Potential, scanning electron microscopy, and agarose gel electrophoresis. Based on the latter technique, a proof-of-concept was established for the proposed immunoassay.
Collapse
Affiliation(s)
- Maria João Oliveira
- UCIBIO, REQUIMTE, Departamento de Química, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, 2829-516 Caparica, Portugal.
- CENIMAT-I3N, Departamento de Ciência dos Materiais, Faculdade de Ciências e Tecnologia, FCT, Universidade Nova de Lisboa, 2829-516 Caparica, Portugal.
| | - Miguel P de Almeida
- REQUIMTE/LAQV, Departamento de Química e Bioquímica, Faculdade de Ciências da Universidade do Porto, 4169-007 Porto, Portugal.
| | - Daniela Nunes
- CENIMAT-I3N, Departamento de Ciência dos Materiais, Faculdade de Ciências e Tecnologia, FCT, Universidade Nova de Lisboa, 2829-516 Caparica, Portugal.
| | - Elvira Fortunato
- CENIMAT-I3N, Departamento de Ciência dos Materiais, Faculdade de Ciências e Tecnologia, FCT, Universidade Nova de Lisboa, 2829-516 Caparica, Portugal.
| | - Rodrigo Martins
- CENIMAT-I3N, Departamento de Ciência dos Materiais, Faculdade de Ciências e Tecnologia, FCT, Universidade Nova de Lisboa, 2829-516 Caparica, Portugal.
| | - Eulália Pereira
- REQUIMTE/LAQV, Departamento de Química e Bioquímica, Faculdade de Ciências da Universidade do Porto, 4169-007 Porto, Portugal.
| | - Hugh J Byrne
- FOCAS Research Institute, Technological University Dublin, Kevin Street, Dublin 8, Ireland.
| | - Hugo Águas
- CENIMAT-I3N, Departamento de Ciência dos Materiais, Faculdade de Ciências e Tecnologia, FCT, Universidade Nova de Lisboa, 2829-516 Caparica, Portugal.
| | - Ricardo Franco
- UCIBIO, REQUIMTE, Departamento de Química, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, 2829-516 Caparica, Portugal.
| |
Collapse
|
37
|
Minetti E, Palermo A, Savadori P, Barlattani A, Franco R, Michele M, Gianfreda F, Bollero P. Autologous tooth graft: a histological comparison between dentin mixed with xenograft and dentin alone grafts in socket preservation. J BIOL REG HOMEOS AG 2019; 33:189-197. [PMID: 32338473] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 06/11/2023]
Abstract
The aim of this study is to compare the histological results after socket preservation between dentin mixed with xenograft and dentin alone in tooth graft procedure. Six patients were included in this prospective case series study and treated in three clinical centers using standardized clinical procedures. This clinical trial enrolled patients with three walls post-extractive defects requiring the restoration of bone dimension and shape in mandibular zone. The patients were divided in two groups: extracted teeth alone (first group) and extracted teeth mixed with equal quantity of xenograft (second group). The extracted tooth was cleaned and processed by a recently introduced automated device, that allows fragmentation and partial demineralization of the tooth matrix and used as graft material. The graft obtained in this way, was inserted at the time of the extraction. A covering membrane was used to protect the graft. Implants were placed after 4 months of healing. Bone biopsies of the all grafted sites were taken at the time of implant surgery, for histological analysis. Descriptive statistics was used to synthesize the results, using mean values and standard deviations. Six patients (5 women, mean age at surgery 50.3±12.1 years) were treated and after 4 months of healing both groups, grafts height appeared stable. No signs of infection were present. Bone biopsy were taken in all grafted sites (3 with group one and 3 with group two). The histologic analysis revealed no inflammatory or infective reaction against both groups. The histomorphometry results between the two groups are different. The first group show an amount of new bone greater than the second group (+85.29%) and minor quantity of residual graft (-83.59%). The dentin alone shows a larger amount of new bone.
Collapse
Affiliation(s)
- E Minetti
- University of Bari "Aldo Moro", Italy, Private Practice, Milan, Italy
| | - A Palermo
- University of Bari "Aldo Moro", Italy, Associate Professor College of Medicine and Dentistry Birmingham, England, Private Practice, Lecce, Italy
| | - P Savadori
- IRCCS Istituto Ortopedico Galeazzi, 20161 Milan, Italy
| | - A Barlattani
- Department of Clinical Sciences and Translational Medicine, University of Rome "Tor Vergata", Rome, Italy
| | - R Franco
- Department of Biomedicine and Prevention, School of Applied Medical-Surgical Sciences, University of Rome Tor Vergata, Rome, Italy
| | - M Michele
- Department of Clinical Sciences and Translational Medicine, University of Rome "Tor Vergata", Rome, Italy
| | - F Gianfreda
- Department of Clinical Sciences and Translational Medicine, University of Rome "Tor Vergata", Rome, Italy
| | - P Bollero
- Department of Systems Medicine, University of Rome "Tor Vergata", Rome, Italy
| |
Collapse
|
38
|
Silveira CM, Zumpano R, Moreira M, Almeida MP, Oliveira MJ, Bento M, Montez C, Paixão I, Franco R, Pereira E, Almeida MG. Star‐Shaped Gold Nanoparticles as Friendly Interfaces for Protein Electrochemistry: the Case Study of Cytochrome
c. ChemElectroChem 2019. [DOI: 10.1002/celc.201901393] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Affiliation(s)
- Célia M. Silveira
- UCIBIO, REQUIMTE Faculdade de Ciências e Tecnologia Universidade NOVA de Lisboa 2829-516 Monte de Caparica Portugal
| | - Rosaceleste Zumpano
- Department of Chemistry and Drug Technologies Sapienza University of Rome Piazzale Aldo Moro 5 00185 Rome Italy
| | - Miguel Moreira
- UCIBIO, REQUIMTE Faculdade de Ciências e Tecnologia Universidade NOVA de Lisboa 2829-516 Monte de Caparica Portugal
| | - Miguel Peixoto Almeida
- LAQV, REQUIMTE, Dep. Química e Bioquímica Faculdade de Ciências Universidade do Porto 4169-007 Porto Portugal
| | - Maria João Oliveira
- UCIBIO, REQUIMTE Faculdade de Ciências e Tecnologia Universidade NOVA de Lisboa 2829-516 Monte de Caparica Portugal
- i3 N/CENIMAT, Dep. Ciência dos Materiais Faculdade de Ciências e Tecnologia Universidade NOVA de Lisboa and CEMOP/UNINOVA 2829-516 Caparica Portugal
| | - Marina Bento
- UCIBIO, REQUIMTE Faculdade de Ciências e Tecnologia Universidade NOVA de Lisboa 2829-516 Monte de Caparica Portugal
| | - Cláudia Montez
- UCIBIO, REQUIMTE Faculdade de Ciências e Tecnologia Universidade NOVA de Lisboa 2829-516 Monte de Caparica Portugal
| | - Inês Paixão
- UCIBIO, REQUIMTE Faculdade de Ciências e Tecnologia Universidade NOVA de Lisboa 2829-516 Monte de Caparica Portugal
| | - Ricardo Franco
- UCIBIO, REQUIMTE Faculdade de Ciências e Tecnologia Universidade NOVA de Lisboa 2829-516 Monte de Caparica Portugal
| | - Eulália Pereira
- LAQV, REQUIMTE, Dep. Química e Bioquímica Faculdade de Ciências Universidade do Porto 4169-007 Porto Portugal
| | - M. Gabriela Almeida
- UCIBIO, REQUIMTE Faculdade de Ciências e Tecnologia Universidade NOVA de Lisboa 2829-516 Monte de Caparica Portugal
- Centro de Investigação Interdisciplinar Egas Moniz (CiiEM) Instituto Superior de Ciências da Saúde Egas Moniz Campus Universitário, Quinta da Granja 2829-511 Caparica Portugal
| |
Collapse
|
39
|
Devereux G, Bourke S, Daines C, Doe S, Dougherty R, Franco R, Innes A, Kopp B, Lascano J, Layish D, McGregor G, Murray L, Peckham D, Smith T, Lucidi V, Volpi S, Lovie E, Robertson J, Fraser-Pitt D, O'Neil D. WS12-6 Evaluating appropriate PROMs in CARE-CF-1 trial: Lynovex® (cysteamine) an oral adjunct to SOC interventions in cystic fibrosis infectious exacebations. J Cyst Fibros 2019. [DOI: 10.1016/s1569-1993(19)30191-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
40
|
de Almeida MP, Leopold N, Franco R, Pereira E. Expedite SERS Fingerprinting of Portuguese White Wines Using Plasmonic Silver Nanostars. Front Chem 2019; 7:368. [PMID: 31179273 PMCID: PMC6543917 DOI: 10.3389/fchem.2019.00368] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2019] [Accepted: 05/06/2019] [Indexed: 11/13/2022] Open
Abstract
Surface-enhanced Raman Spectrosocopy (SERS) is a highly sensitive form of Raman spectroscopy, with strong selectivity for Raman-active molecules adsorbed to plasmonic nanostructured surfaces. Extremely intense Raman signals derive from "hotspots", generally created by the aggregation of a silver nanospheres colloid. An alternative and cleaner approach is the use of anisotropic silver nanoparticles, with intrinsic "hotspots", allowing a more controlled enhancement effect as it is not dependent on disordered nanoparticle aggregation. Here, a simple SERS-based test is proposed for Portuguese white wines fingerprinting. The test is done by mixing microliter volumes of a silver nanostars colloid and the white wine sample. SERS spectra obtained directly from these mixtures, with no further treatments, are analyzed by principal component analysis (PCA), using a dedicated software. Depending on the duration of the incubation period, different discrimination can be obtained for the fingerprinting. A "mix-and-read" approach, with practically no incubation, allows for a simple discrimination between the three white wines tested. An overnight incubation allows for full discrimination between varieties of wine (Verde or Maduro), as well as between wines from different Maduro wine regions. This use of SERS in a straightforward, fast and inexpensive test for wine fingerprinting, avoiding the need for prior sample treatment, paves the way for the development of a simple and inexpensive authenticity assay for wines from specific appellations.
Collapse
Affiliation(s)
- Miguel Peixoto de Almeida
- LAQV, REQUIMTE, Departamento de Química e Bioquímica, Faculdade de Ciências da Universidade do Porto, Porto, Portugal
| | - Nicolae Leopold
- Faculty of Physics, Babeş-Bolyai University, Cluj-Napoca, Romania
| | - Ricardo Franco
- UCIBIO, REQUIMTE, Departamento de Química, Faculdade de Ciências e Tecnologia, Universidade NOVA de Lisboa, Caparica, Portugal
| | - Eulália Pereira
- LAQV, REQUIMTE, Departamento de Química e Bioquímica, Faculdade de Ciências da Universidade do Porto, Porto, Portugal
| |
Collapse
|
41
|
Kim HN, Nance RM, Williams-Nguyen JS, Chris Delaney JA, Crane HM, Cachay ER, Martin J, Mathews WC, Chander G, Franco R, Hurt CB, Geng EH, Rodriguez B, Moore RD, Saag MS, Kitahata MM. Effectiveness of Direct-Acting Antiviral Therapy in Patients With Human Immunodeficiency Virus-Hepatitis C Virus Coinfection in Routine Clinical Care: A Multicenter Study. Open Forum Infect Dis 2019; 6:ofz100. [PMID: 30949539 PMCID: PMC6441587 DOI: 10.1093/ofid/ofz100] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/11/2018] [Accepted: 02/25/2019] [Indexed: 02/06/2023] Open
Abstract
Background Direct-acting antiviral (DAA) therapy have been shown to be highly successful in clinical trials and observational studies, but less is known about treatment success in patients with a high burden of comorbid conditions, including mental health and substance use disorders. We evaluated DAA effectiveness across a broad spectrum of patients with human immunodeficiency virus (HIV)-hepatitis C virus (HCV) coinfection in routine clinical care, including those with psychosocial comorbid conditions. Methods The primary end point was sustained virologic response (SVR), defined as HCV RNA not detected or <25 IU/mL ≥10 weeks after treatment. We calculated SVR rates and 95% confidence intervals (CIs) in a modified intent-to-treat analysis. We repeated this analysis after multiply imputing missing SVR values. Results Among 642 DAA-treated patients, 536 had SVR assessments. The median age was 55 years; 79% were men, 59% black, and 32% white. Cirrhosis (fibrosis-4 index>3.25) was present in 24%, and 17% were interferon treatment experienced; 96% had genotype 1 infection and 432 (81%) had received ledipasvir-sofosbuvir. SVR occurred in 96.5% (95% CI, 94.5%-97.9%). Patients who were black, treatment experienced, or cirrhotic all had SVR rates >95%. Patients with depression and/or anxiety, psychotic disorder, illicit drug use, or alcohol use disorder also had high SVR rates, ranging from 95.4% to 96.8%. The only factor associated with lower SVR rate was early discontinuation (77.8%; 95% CI, 52.4%-93.6%). Similar results were seen in multiply imputed data sets. Conclusions Our study represents a large multicenter examination of DAA therapy in HIV/HCV-coinfected patients. The broad treatment success we observed across this diverse group of patients with significant comorbid conditions is highly affirming and argues for widespread implementation of DAA therapy.
Collapse
Affiliation(s)
- H Nina Kim
- Department of Medicine, University of Washington, Seattle
| | - Robin M Nance
- Department of Medicine, University of Washington, Seattle
| | | | | | - Heidi M Crane
- Department of Medicine, University of Washington, Seattle
| | | | - Jeffrey Martin
- Department of Medicine, University of California, San Francisco
| | | | | | - Ricardo Franco
- Department of Medicine, University of Alabama, Birmingham
| | - Christopher B Hurt
- Institute for Global Health & Infectious Diseases, University of North Carolina, Chapel Hill
| | - Elvin H Geng
- Department of Medicine, University of California, San Francisco
| | | | - Richard D Moore
- Department of Medicine, Johns Hopkins University, Baltimore, Maryland
| | - Michael S Saag
- Department of Medicine, University of Alabama, Birmingham
| | | | | |
Collapse
|
42
|
Caro C, Quaresma P, Pereira E, Franco J, Pernia Leal M, García-Martín ML, Royo JL, Oliva-Montero JM, Merkling PJ, Zaderenko AP, Pozo D, Franco R. Synthesis and Characterization of Elongated-Shaped Silver Nanoparticles as a Biocompatible Anisotropic SERS Probe for Intracellular Imaging: Theoretical Modeling and Experimental Verification. Nanomaterials (Basel) 2019; 9:nano9020256. [PMID: 30781838 PMCID: PMC6409692 DOI: 10.3390/nano9020256] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 12/27/2018] [Revised: 02/01/2019] [Accepted: 02/09/2019] [Indexed: 01/07/2023]
Abstract
Progress in the field of biocompatible SERS nanoparticles has promising prospects for biomedical applications. In this work, we have developed a biocompatible Raman probe by combining anisotropic silver nanoparticles with the dye rhodamine 6G followed by subsequent coating with bovine serum albumin. This nanosystem presents strong SERS capabilities in the near infrared (NIR) with a very high (2.7 × 107) analytical enhancement factor. Theoretical calculations reveal the effects of the electromagnetic and chemical mechanisms in the observed SERS effect for this nanosystem. Finite element method (FEM) calculations showed a considerable near field enhancement in NIR. Using density functional quantum chemical calculations, the chemical enhancement mechanism of rhodamine 6G by interaction with the nanoparticles was probed, allowing us to calculate spectra that closely reproduce the experimental results. The nanosystem was tested in cell culture experiments, showing cell internalization and also proving to be completely biocompatible, as no cell death was observed. Using a NIR laser, SERS signals could be detected even from inside cells, proving the applicability of this nanosystem as a biocompatible SERS probe.
Collapse
Affiliation(s)
- Carlos Caro
- Department of Physical, Chemical and Natural Systems, Universidad Pablo de Olavide, Carretera de Utrera Km 1, 41013 Seville, Spain.
- Departamento de Química, UCIBIO, REQUIMTE, Faculdade de Ciências, Universidade NOVA de Lisboa, 2829-516 Caparica, Portugal.
- CABIMER, Andalusian Center for Molecular Biology and Regenerative Medicine, Av. Americo Vespucio, 24, 41092 Sevilla, Spain.
- BIONAND, Andalusian Centre for Nanomedicine and Biotechnology, Junta de Andalucía, Universidad de Málaga, 29590 Málaga, Spain.
| | - Pedro Quaresma
- Departamento de Química e Bioquímica, LAQV-REQUIMTE, Faculdade de Ciências, Universidade do Porto, 4169-007 Porto, Portugal.
| | - Eulália Pereira
- Departamento de Química e Bioquímica, LAQV-REQUIMTE, Faculdade de Ciências, Universidade do Porto, 4169-007 Porto, Portugal.
| | - Jaime Franco
- CABIMER, Andalusian Center for Molecular Biology and Regenerative Medicine, Av. Americo Vespucio, 24, 41092 Sevilla, Spain.
- Department of Medical Biochemistry, Molecular Biology and Immunology, Universidad de Sevilla, Av. Sanchez Pizjuan, 4, 41009 Sevilla, Spain.
| | - Manuel Pernia Leal
- BIONAND, Andalusian Centre for Nanomedicine and Biotechnology, Junta de Andalucía, Universidad de Málaga, 29590 Málaga, Spain.
- Department of Organic and Pharmaceutical Chemistry, Universidad de Sevilla, 41012 Seville, Spain.
| | - Maria Luisa García-Martín
- BIONAND, Andalusian Centre for Nanomedicine and Biotechnology, Junta de Andalucía, Universidad de Málaga, 29590 Málaga, Spain.
| | - Jose Luis Royo
- Department of Biochemistry, Molecular Biology and Immunology, Universidad de Málaga, 29071 Málaga, Spain.
| | - Jose Maria Oliva-Montero
- Department of Physical, Chemical and Natural Systems, Universidad Pablo de Olavide, Carretera de Utrera Km 1, 41013 Seville, Spain.
| | - Patrick Jacques Merkling
- Department of Physical, Chemical and Natural Systems, Universidad Pablo de Olavide, Carretera de Utrera Km 1, 41013 Seville, Spain.
| | - Ana Paula Zaderenko
- Department of Physical, Chemical and Natural Systems, Universidad Pablo de Olavide, Carretera de Utrera Km 1, 41013 Seville, Spain.
| | - David Pozo
- CABIMER, Andalusian Center for Molecular Biology and Regenerative Medicine, Av. Americo Vespucio, 24, 41092 Sevilla, Spain.
- Department of Medical Biochemistry, Molecular Biology and Immunology, Universidad de Sevilla, Av. Sanchez Pizjuan, 4, 41009 Sevilla, Spain.
| | - Ricardo Franco
- Departamento de Química, UCIBIO, REQUIMTE, Faculdade de Ciências, Universidade NOVA de Lisboa, 2829-516 Caparica, Portugal.
| |
Collapse
|
43
|
Affiliation(s)
- E Moscarella
- Dermatology Unit, University of Campania, Nuovo Policlinico (Edificio 9C), Via Pansini 5, 80131, Naples, Italy
| | - A Ronchi
- Pathology Unit, University of Campania, Nuovo Policlinico (Edificio 9C), Via Pansini 5, 80131, Naples, Italy
| | - M Agozzino
- Dermatology Unit, University of Campania, Nuovo Policlinico (Edificio 9C), Via Pansini 5, 80131, Naples, Italy
| | - R Franco
- Pathology Unit, University of Campania, Nuovo Policlinico (Edificio 9C), Via Pansini 5, 80131, Naples, Italy
| | - G Argenziano
- Dermatology Unit, University of Campania, Nuovo Policlinico (Edificio 9C), Via Pansini 5, 80131, Naples, Italy
| |
Collapse
|
44
|
Brancaccio G, Napolitano S, Troiani T, Franco R, Iovino F, Reginelli A, Ciardiello F, Argenziano G. Eighth American Joint Committee on Cancer (AJCC) melanoma classification: what about stage IIC? Br J Dermatol 2018; 179:1422-1423. [DOI: 10.1111/bjd.17145] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- G. Brancaccio
- Dermatology Unit; Department of Internal & Experimental Medicine ‘F Magrassi’; University of Campania ‘Luigi Vanvitelli’; Via Pansini 5 80131 Naples Italy
| | - S. Napolitano
- Oncology Unit; Department of Internal & Experimental Medicine ‘F Magrassi’; University of Campania ‘Luigi Vanvitelli’; Via Pansini 5 80131 Naples Italy
| | - T. Troiani
- Oncology Unit; Department of Internal & Experimental Medicine ‘F Magrassi’; University of Campania ‘Luigi Vanvitelli’; Via Pansini 5 80131 Naples Italy
| | - R. Franco
- Pathology Unit; Department of Cardiothoracic and Respiratory Science; University of Campania ‘Luigi Vanvitelli’; Via Pansini 5 80131 Naples Italy
| | - F. Iovino
- Division of General Surgery; Department of Cardiothoracic and Respiratory Science; University of Campania ‘Luigi Vanvitelli’; Via Pansini 5 80131 Naples Italy
| | - A. Reginelli
- Department of Radiology & Radiotherapy, Department of Internal & Experimental Medicine ‘F Magrassi’; University of Campania ‘Luigi Vanvitelli’; Via Pansini 5 80131 Naples Italy
| | - F. Ciardiello
- Oncology Unit; Department of Internal & Experimental Medicine ‘F Magrassi’; University of Campania ‘Luigi Vanvitelli’; Via Pansini 5 80131 Naples Italy
| | - G. Argenziano
- Dermatology Unit; Department of Internal & Experimental Medicine ‘F Magrassi’; University of Campania ‘Luigi Vanvitelli’; Via Pansini 5 80131 Naples Italy
| |
Collapse
|
45
|
Zito Marino F, Accardo M, Poziello G, Ronchi A, Ciaramella V, Vicidomini G, Santini M, Morgillo F, Franco R. P2.06-42 AXL, c-MET and VEGFR2 Tyrosine Kinase Receptors as Therapeutic Targets in Malignant Pleural Mesothelioma. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1297] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
|
46
|
Orditura M, Della Corte CM, Diana A, Ciaramella V, Franzese E, Famiglietti V, Panarese I, Franco R, Grimaldi A, Lombardi A, Caraglia M, Santoriello A, Procaccini E, Lieto E, Maiello E, De Vita F, Ciardiello F, Morgillo F. Three dimensional primary cultures for selecting human breast cancers that are sensitive to the anti-tumor activity of ipatasertib or taselisib in combination with anti-microtubule cytotoxic drugs. Breast 2018; 41:165-171. [PMID: 30103105 DOI: 10.1016/j.breast.2018.08.002] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/05/2018] [Revised: 07/16/2018] [Accepted: 08/01/2018] [Indexed: 12/21/2022] Open
Abstract
Two inhibitors of phosphatidylinositol 3-kinase (PI3K) pathway taselisib, targeting the mutant PI3K-subunit-alpha (PI3KA) and ipatasertib, AKT-inhibitor, are currently under clinical investigation in breast cancer (BC) patients. We have previously demonstrated the anti-tumor efficacy of these anti-PI3K/AKT-inibitors in combination with anti-microtubule drugs in human BC cell lines, through a complete cytoskeleton disorganization. In this work, we generated ex-vivo three-dimensional (3D) cultures from human BC as a model to test drug efficacy and to identify new molecular biomarkers for selection of BC patients suitable for anti-PI3K/AKT-inibitors treatment. We have established 3D cultures from 25/27 human BC samples, in which the ability of growth in vitro replicates the clinical and biological aggressiveness of the original tumors. According to the results of next generation sequencing analysis, a direct correlation was found between PI3KA mutations and the sensitivity in 3D models in vitro to taselisib and ipatasertib alone and combined with anti-microtubule agents. Moreover, mutations in HER and MAPK families related genes, including EGFR, KRAS and BRAF, were found in resistant samples, suggesting their potential role as negative predictive factors of response to these agents. Thus, we demonstrated that ex vivo 3D cultures from human BC patients allow a rapid and efficient drug screening for chemotherapies and targeted agents in genetically selected patients and represent an innovative model to identify new biomarkers of drug resistance.
Collapse
Affiliation(s)
- M Orditura
- Oncology, Universita degli Studi della Campania Luigi Vanvitelli, Napoli, Italy.
| | - C M Della Corte
- Oncology, Universita degli Studi della Campania Luigi Vanvitelli, Napoli, Italy.
| | - A Diana
- Oncology, Universita degli Studi della Campania Luigi Vanvitelli, Napoli, Italy.
| | - V Ciaramella
- Oncology, Universita degli Studi della Campania Luigi Vanvitelli, Napoli, Italy.
| | - E Franzese
- Oncology, Universita degli Studi della Campania Luigi Vanvitelli, Napoli, Italy.
| | - V Famiglietti
- Oncology, Universita degli Studi della Campania Luigi Vanvitelli, Napoli, Italy.
| | - I Panarese
- Pathology Unit, Universita degli Studi della Campania Luigi Vanvitelli, Napoli, Italy.
| | - R Franco
- Pathology Unit, Universita degli Studi della Campania Luigi Vanvitelli, Napoli, Italy.
| | - A Grimaldi
- Department of Biochemistry, Biophysics and General Pathology, Universita degli Studi della Campania Luigi Vanvitelli, Napoli, Italy.
| | - A Lombardi
- Department of Biochemistry, Biophysics and General Pathology, Universita degli Studi della Campania Luigi Vanvitelli, Napoli, Italy.
| | - M Caraglia
- Department of Biochemistry, Biophysics and General Pathology, Universita degli Studi della Campania Luigi Vanvitelli, Napoli, Italy.
| | - A Santoriello
- Breast Unit Surgery, Universita degli Studi della Campania Luigi Vanvitelli, Napoli, Italy.
| | - E Procaccini
- Breast Unit Surgery, Universita degli Studi della Campania Luigi Vanvitelli, Napoli, Italy.
| | - E Lieto
- Surgery 9th Division, Universita degli Studi della Campania Luigi Vanvitelli, Napoli, Italy.
| | - E Maiello
- Department of Oncology, Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy.
| | - F De Vita
- Oncology, Universita degli Studi della Campania Luigi Vanvitelli, Napoli, Italy.
| | - F Ciardiello
- Oncology, Universita degli Studi della Campania Luigi Vanvitelli, Napoli, Italy.
| | - F Morgillo
- Oncology, Universita degli Studi della Campania Luigi Vanvitelli, Napoli, Italy.
| |
Collapse
|
47
|
Buczko W, Gaetano GD, Franco R, Donati MB. Biological Properties of Dialysable Peptides Derived from Plasmin Digestion of Bovine Fibrinogen Preparations. Thromb Haemost 2018. [DOI: 10.1055/s-0038-1647964] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
SummaryDialysable peptides (M. W. less than 12,000) were obtained by plasmin digests of purified bovine fibrinogen. The biological effects of these peptides were studied in rats in three different test systems: ADP-induced platelet aggregation, isolated atria contractility and vascular permeability.The effects induced by the peptides were: inhibition of ADP-induced platelet aggregation, increase in the frequency of isolated atria contractions and local increase in vascular permeability. All these activities were concentration dependent. Six micrograms of the peptides were still effective in increasing vascular permeability; in the in vitro systems the smallest effective dose ranged between 165 and 650 μg/ml.Following elution through a Sephadex G-25 gel with bidistilled water, four fractions were obtained. The second fraction (M.W. about 5,000) was the most active, followed by the first and then the third one; the fourth fraction was inactive.These data suggest that local accumulation of peptides in vivo may be of clinical relevancy.
Collapse
|
48
|
Peixoto de Almeida M, Quaresma P, Sousa S, Couto C, Gomes I, Krippahl L, Franco R, Pereira E. Measurement of adsorption constants of laccase on gold nanoparticles to evaluate the enhancement in enzyme activity of adsorbed laccase. Phys Chem Chem Phys 2018; 20:16761-16769. [PMID: 29882945 DOI: 10.1039/c8cp03116a] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
Abstract
Adsorption of enzymes to nanoparticles and the mechanisms responsible for enzyme activity modulation of adsorbed enzymes are not well understood. In this work, gold nanoparticles were used for electrostatic adsorption of a plant-derived laccase. Adsorption constants were determined by four independent techniques: dynamic light scattering, electrophoretic light scattering, agarose gel electrophoresis and fluorescence quenching. Stable bionanoconjugates were formed with log K in the range 6.8-8.9. An increase in enzyme activity was detected, in particular at acidic and close to neutral pH values, a feature that expands the useful pH range of the enzyme. A model for the adsorption was developed, based on geometrical considerations and volume increase data from dynamic light scattering. This indicates that enzymes adsorbed to gold nanoparticles are ca. 9 times more active than the free enzyme.
Collapse
Affiliation(s)
- Miguel Peixoto de Almeida
- LAQV, REQUIMTE, Departamento de Química e Bioquímica, Rua do Campo Alegre s/n, 4169-007 Porto, Portugal.
| | | | | | | | | | | | | | | |
Collapse
|
49
|
Bruno RM, Stea F, Sicari R, Ghiadoni L, Taddei S, Ungar A, Bonuccelli U, Tognoni G, Cintoli S, Del Turco S, Sbrana S, Gargani L, D’Angelo G, Pratali L, Berardi N, Maffei L, Picano E, Andreassi M, Angelucci A, Baldacci F, Baroncelli L, Begenisic T, Bellinvia P, Biagi L, Bonaccorsi J, Bonanni E, Borghini A, Braschi C, Broccardi M, Caleo M, Carlesi C, Carnicelli L, Cartoni G, Cecchetti L, Cenni M, Ceravolo R, Chico L, Cioni G, Costa M, D’Ascanio P, De Nes M, Di Coscio E, Di Galante M, di Lascio N, Faita F, Falorni I, Faraguna U, Fenu A, Fortunato L, Franco R, Gargiulo R, Giorgi F, Iannarella R, Iofrida C, Kusmic C, Limongi F, Maestri M, Maffei M, Maggi S, Mainardi M, Mammana L, Marabotti A, Mariotti V, Melissari E, Mercuri A, Molinaro S, Narducci R, Navarra T, Noale M, Pagni C, Palumbo S, Pasquariello R, Pellegrini S, Pietrini P, Pizzorusso T, Poli A, Retico A, Ricciardi E, Rota G, Sale A, Scabia G, Scali M, Scelfo D, Siciliano G, Tonacci A, Tosetti M, Turchi S, Volpi L. Vascular Function Is Improved After an Environmental Enrichment Program. Hypertension 2018; 71:1218-1225. [DOI: 10.1161/hypertensionaha.117.10066] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/25/2017] [Revised: 08/09/2017] [Accepted: 03/15/2018] [Indexed: 11/16/2022]
Abstract
Environmental enrichment may slow cognitive decay possibly acting through an improvement in vascular function. Aim of the study was to assess the effects of a 7-month cognitive, social, and physical training program on cognitive and vascular function in patients with mild cognitive impairment. In a single-center, randomized, parallel-group study, 113 patients (age, 65–89 years) were randomized to multidomain training (n=55) or usual care (n=58). All participants underwent neuropsychological tests and vascular evaluation, including brachial artery flow-mediated dilation, carotid–femoral pulse wave velocity, carotid distensibility, and assessment of circulating hematopoietic CD34+ and endothelial progenitor cells. At study entry, an age-matched control group (n=45) was also studied. Compared with controls, patients had at study entry a reduced flow-mediated dilation (2.97±2.14% versus 3.73±2.06%;
P
=0.03) and hyperemic stimulus (shear rate area under the curve, 19.1±15.7 versus 25.7±15.1×10
−3
;
P
=0.009); only the latter remained significant after adjustment for confounders (
P
=0.03). Training improved Alzheimer disease assessment scale cognitive (training, 14.0±4.8 to 13.1±5.5; nontraining, 12.1±3.9 to 13.2±4.8;
P
for interaction visit×training=0.02), flow-mediated dilation (2.82±2.19% to 3.40±1.81%, 3.05±2.08% to 2.24±1.59%;
P
=0.006;
P
=0.023 after adjustment for diameter and shear rate area under the curve), and circulating hematopoietic CD34
+
cells and prevented the decline in carotid distensibility (18.4±5.3 to 20.0±6.6, 23.9±11.0 to 19.5±7.1 Pa
−1
;
P
=0.005). The only clinical predictor of improvement of cognitive function after training was established hypertension. There was no correlation between changes in measures of cognitive and vascular function. In conclusion, a multidomain training program slows cognitive decline, especially in hypertensive individuals. This effect is accompanied by improved systemic endothelial function, mobilization of progenitor CD34
+
cells, and preserved carotid distensibility.
Clinical Trial Registration—
URL:
http://www.clinicaltrials.gov
. Unique identifier: NCT01725178.
Collapse
Affiliation(s)
- Rosa Maria Bruno
- From the Department of Clinical and Experimental Medicine, University of Pisa, Italy (R.M.B., F.S., L.G., S.T., U.B.)
- Institute of Clinical Physiology of the National Research Council (CNR), Pisa, Italy (R.M.B., F.S., R.S., S.D.T., S.S., L.G., G.D., L.P., E.P.)
| | - Francesco Stea
- From the Department of Clinical and Experimental Medicine, University of Pisa, Italy (R.M.B., F.S., L.G., S.T., U.B.)
- Institute of Clinical Physiology of the National Research Council (CNR), Pisa, Italy (R.M.B., F.S., R.S., S.D.T., S.S., L.G., G.D., L.P., E.P.)
| | - Rosa Sicari
- Institute of Clinical Physiology of the National Research Council (CNR), Pisa, Italy (R.M.B., F.S., R.S., S.D.T., S.S., L.G., G.D., L.P., E.P.)
| | - Lorenzo Ghiadoni
- From the Department of Clinical and Experimental Medicine, University of Pisa, Italy (R.M.B., F.S., L.G., S.T., U.B.)
| | - Stefano Taddei
- From the Department of Clinical and Experimental Medicine, University of Pisa, Italy (R.M.B., F.S., L.G., S.T., U.B.)
| | | | - Ubaldo Bonuccelli
- From the Department of Clinical and Experimental Medicine, University of Pisa, Italy (R.M.B., F.S., L.G., S.T., U.B.)
| | - Gloria Tognoni
- Azienda Ospedaliero Universitaria Careggi, University of Florence, Italy (A.U.); Azienda Ospedaliero Universitaria Pisana, Italy (G.T., S.C.)
| | - Simona Cintoli
- Azienda Ospedaliero Universitaria Careggi, University of Florence, Italy (A.U.); Azienda Ospedaliero Universitaria Pisana, Italy (G.T., S.C.)
| | - Serena Del Turco
- Institute of Clinical Physiology of the National Research Council (CNR), Pisa, Italy (R.M.B., F.S., R.S., S.D.T., S.S., L.G., G.D., L.P., E.P.)
| | - Silverio Sbrana
- Institute of Clinical Physiology of the National Research Council (CNR), Pisa, Italy (R.M.B., F.S., R.S., S.D.T., S.S., L.G., G.D., L.P., E.P.)
| | - Luna Gargani
- Institute of Clinical Physiology of the National Research Council (CNR), Pisa, Italy (R.M.B., F.S., R.S., S.D.T., S.S., L.G., G.D., L.P., E.P.)
| | - Gennaro D’Angelo
- Institute of Clinical Physiology of the National Research Council (CNR), Pisa, Italy (R.M.B., F.S., R.S., S.D.T., S.S., L.G., G.D., L.P., E.P.)
| | - Lorenza Pratali
- Institute of Clinical Physiology of the National Research Council (CNR), Pisa, Italy (R.M.B., F.S., R.S., S.D.T., S.S., L.G., G.D., L.P., E.P.)
| | | | | | - Eugenio Picano
- Institute of Clinical Physiology of the National Research Council (CNR), Pisa, Italy (R.M.B., F.S., R.S., S.D.T., S.S., L.G., G.D., L.P., E.P.)
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
50
|
Trolio RDI, Lorenzo GDI, Barberio E, Iacono A, Franco R, D'Armient0 M, Delfino M, D'Armiento F. Expression of HECA-452 in Parapsoriasis and Mycosis Fungoides. Int J Immunopathol Pharmacol 2018. [DOI: 10.1177/205873920601900110] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023] Open
Abstract
We have investigated the HECA-452 expression in large plaque parapsoriasis (PP) and mycosis fungoides (MF) patients, evaluating the potential role of this biomarker in both cutaneous disorders. Skin specimens from 72 PP and 61 MF patients were selected in this study. We compared their actual histological diagnosis with their previous diagnosis and we found that all 72 PP patients had the same diagnosis as before (stable PP), while 26 out of 61 MF have a previous PP histological diagnosis (evolving PP). Our results show an increased expression of HECA-452 in MF compared to PP (p<0.01). Furthermore, evolving PP showed a significantly higher level of HECA-452 than stable PP (p< 0.05). We conclude that HECA-452 expression increases during the natural history of Mycosis Fungoides. HECA-452 could be used as a biomarker for MF and predict which PP evolves to MF.
Collapse
Affiliation(s)
- R. DI Trolio
- Dipartimento di Patologia Sistematica-Clinica Dermatologica, Università degli Studi di Napoli Federico II, Naples, Italy
| | - G. DI Lorenzo
- Cattedra di Oncologia Medica, Università degli Studi di Napoli Federico II, Naples, Italy
| | - E. Barberio
- Dipartimento di Patologia Sistematica-Clinica Dermatologica, Università degli Studi di Napoli Federico II, Naples, Italy
| | - A. Iacono
- Dipartimento di Scienze Biomorfologiche e Funzionali, Università degli Studi di Napoli Federico II, Naples, Italy
| | - R. Franco
- Dipartimento di Scienze Biomorfologiche e Funzionali, Università degli Studi di Napoli Federico II, Naples, Italy
| | - M. D'Armient0
- Dipartimento di Scienze Biomorfologiche e Funzionali, Università degli Studi di Napoli Federico II, Naples, Italy
| | - M. Delfino
- Dipartimento di Patologia Sistematica-Clinica Dermatologica, Università degli Studi di Napoli Federico II, Naples, Italy
| | - F.P. D'Armiento
- Dipartimento di Scienze Biomorfologiche e Funzionali, Università degli Studi di Napoli Federico II, Naples, Italy
| |
Collapse
|